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ABSTRACT 
 
 
 
PepT1 (SLC15A1) is a transporter apically expressed along the epithelial cells of 
the gastrointestinal tract and is responsible for the absorption of di/tripeptides, ACE 
inhibitors, B-lactam antibiotics and numerous prodrugs. Unfortunately, PepT1-mediated 
substrates that have been extensively studied were shown to exhibit species-dependent 
absorption and pharmacokinetics. Accordingly, in situ intestinal perfusion studies were 
conducted and valacyclovir uptake was shown to have a 30-fold lower Km and 100-fold 
lower Vmax in huPepT1 compared to wildtype mice.  Moreover, inhibition studies 
demonstrated that the huPepT1 transporter alone was responsible for valacyclovir 
uptake, and segment-dependent studies reported significant reductions in permeability 
along the length of small intestine in huPepT1 mice.  Subsequent oral administration 
studies revealed that the in vivo rate and extent of valacyclovir absorption were lower in 
huPepT1 mice, as indicated by 3-fold lower Cmax and 3-fold higher Tmax values, and an 
AUC0-180 that was 80% of that observed in wildtype mice. However, no significant 
changes in drug disposition were observed between genotypes after intravenous bolus 
administration of acyclovir. Lastly, mass balance studies established that the 
bioavailability of acyclovir, after oral dosing of valacyclovir, was 77.5% in wildtype mice 
and 52.8% in huPepT1 mice, which corroborated values of 51.3% in clinical studies. 
Thus, it appears the huPepT1 transgenic mice may be a better model to study prodrug 
absorption and disposition in humans than wildtype mice.   
xv 
 
Additional studies were conducted to determine the impact of nifedipine, a 
calcium channel blocker, on the PepT1-mediated uptake of valacyclovir in wildtype 
mice.  It has been previously demonstrated in clinical studies, rat intestinal perfusion 
studies, and Caco-2 uptake studies that nifedipine enhanced the absorption of β-lactam 
antibiotics.  However, co-perfusing nifedipine with valacyclovir revealed that the 
intestinal permeability of valacyclovir was not significantly altered in the presence of this 
calcium channel blocker, although a 25-30% reduction was observed.  While the results 
obtained in these studies are difficult to reconcile, there may be a species-dependent 
mechanism in mice that negates the permeability enhancement of PepT1 substrates.   
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CHAPTER 1 
 
Research Objectives 
 
 
 
Mammalian members of the proton-coupled oligopeptide transporter (POT) 
family include PepT1 (SLC15A1), PepT2 (SLC15A2), PhT1 (SLC15A4), and PhT2 
(SLC15A3).  PepT1 is apically expressed mainly in the epithelial cells lining the lumen 
of the small intestine.  It is a low-affinity, high-capacity transporter that mediates the 
absorption of dietary peptides along with peptidomimetic compounds with therapeutic 
significance such as angiotensin-converting enzyme (ACE) inhibitors, β-lactam 
antibiotics, and prodrugs such as valacyclovir. 
 Valacyclovir is the L-valyl ester prodrug of acyclovir, a nucleoside analog utilized 
as an antiviral agent.  A multitude of in vitro cell culture studies have demonstrated the 
pH-dependent, concentration-dependent, and saturable nature of valacyclovir transport 
attributable to PepT1.  Moreover, in situ perfusions in wildtype and PepT1 knockout 
(Pept1-/-) mice have definitively proven that PepT1 is responsible for more than 80% of 
valacyclovir uptake across intestinal enterocytes. 
 However, a distinguishing characteristic of valacyclovir is that the prodrug 
exhibits species-dependent pharmacokinetics.  While escalating oral doses of 
valacyclovir in mice have demonstrated linear pharmacokinetics, clinical administration 
studies revealed less than proportional, nonlinear trends.  These differences are 
believed to be due to the intrinsic and distinctive transporter activity of the mouse and 
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human PepT1 orthologues.   In order to investigate this premise, the intestinal and oral 
absorption of valacyclovir would need to be characterized in wildtype and huPepT1 
transgenic mice.   
Additionally, there has been a prevailing interest in investigating drug-drug 
interactions that impact the absorption and bioavailability of PepT1 substrates.  A 
number of studies from the literature have shown that the calcium channel blocker 
nifedipine enhances the intestinal and oral absorption of various β-lactam antibiotics.  
However, this interaction has yet to be verified with other PepT1 substrates, such as 
with the prodrug valacyclovir. 
The research objectives for this work are as follows:  
 
1) To characterize and compare the intestinal permeability of valacyclovir between 
wildtype and huPepT1 mice 
2) To characterize and compare the in vivo oral absorption and pharmacokinetics of 
valacyclovir in wildtype and huPepT1 mice 
3) To investigate the potential drug-drug interaction between valacyclovir and 
nifedipine in wildtype mice via intestinal perfusions 
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CHAPTER 2 
 
Background and Literature Review 
 
 
 
2.1 Structure and Transport Properties of the Small Intestine 
 
 
 
The human small intestine is approximately six meters long and can be                      
subdivided into the duodenum (25 cm), jejunum (2.5 m), and ileum (3.5m).  As the 
major absorptive site of nutrients, its surface area is maximized by the inclusion of 
circular folds, villi, and microvilli.  Villi are 0.5-1.5 mm finger-like projections emanating 
from the mucosal layer and are enriched by extensive capillary beds.  At the base of 
each villus, glands secrete mucus to combat acidic stomach chime. As a consequence, 
intraluminal pH will vary from 6 in the duodenum to 7.4 in the distal ileum (Fallingborg 
et. al, 1999). Covering each villus are hair-like projections called microvilli. These 
microvilli are comprised of epithelial cells: the major site for nutrient uptake and 
enzymatic degradation (Johnstone et. al, 2014).                                                                                                                        
Transport across epithelial cells can either be mediated by transcellular or 
paracellular processes.  Transcellular processes include endocytosis, passive diffusion, 
and carrier-mediated transport.  Hydrophilic drugs, metabolites, toxins, and endogenous 
compounds primarily need carriers to circumvent the large hydrophobic lipid bilayer 
(Pade and Stavchansky, 1997; Oostendorp et. al, 2009).  The transporters responsible 
for absorption in the small intestine belong in two super-families: the ATP-binding 
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cassette (ABC) efflux transporters and the solute carrier (SLC) family.  Important ABC 
efflux transporters include multidrug resistance proteins (MRPs), P-glycoproteins (P-
gps), and the breast cancer resistance protein (BCRP).  Major SLC transporters include 
organic anion transporters (OATs), organic cation transporters (OCTs), 
monocarboxylate transporters (MCTs), nucleoside transporters (CNTs, ENTs), and 
proton-coupled oligopeptide transporters (POTs) (Zakeri-Milani and Valizadeh, 2014).  
Conversely, the paracellular pathway involves the claudin-dependent diffusion of ions, 
water flux, and the passive transport of small molecules (i.e. <3.6 Å) like glucose and 
mannitol (Turner et. al, 2014). 
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2.2  Proton-Coupled Oligopeptide Transporter (POT) Family 
 
  
 
Proton-coupled oligopeptide transporters (POTs) are a family of transport 
proteins that facilitate the transfer of di- and tri-peptides along with peptidomimetics 
across cell membranes.  The four mammalian members of this family include PepT1 
(SLC15A1), PepT2 (SLC15A2), PhT1 (SLC15A4), and PhT2 (SLC15A3) (Smith et. al, 
2013).  PepT1 was the first member successfully cloned by isolation from a rabbit 
intestinal cDNA library (Kanai, 1994). PepT2 shortly followed as the second member to 
be identified and cloned from a human renal cDNA library (Liu et al, 1995).  PhT1 and 
PhT2 were later identified and cloned from a rat brain cDNA library (Yamashita et. al, 
1997; Sakata et. al, 2001). 
PepT1 and PepT2 have been the most studied POTs to date.  While both 
transporters share similar substrate specificities, they differ in several ways.  Human 
PepT1 and PepT2 share approximately a 50% amino acid sequence identity, with their 
chains being 708 and 729 residues long respectively (Daniel and Kottra, 2004). While 
PepT1 is a low-affinity high-capacity transporter with substrate Km values between 200 
μM to 10 mM, PepT2 is a high-affinity low-capacity transporter with substrate Km values 
between 5 and 500 μM.  Physiologically, PepT1 is mainly expressed in the small 
intestine, with lower expression in some tissues such as the kidney, bile duct, pancreas, 
liver, and placenta (Herrera-Ruiz et. al, 2001; Daniel and Herget, 1997). In contrast, 
PepT2 expression is highest in the proximal tubule of the kidneys, with appreciable 
levels also located in the central nervous system, lungs, and mammary glands (Döring 
et. al, 1998; Rubio-Aliaga and Daniel; 2002, Wang et. al, 2010). 
6 
 
Less information is known about the PhT1 and PhT2 transporters.  While they 
can mediate the transport of certain di- and tri-peptides, their ability to shuttle histidine 
across cell membranes differentiates them from other POT members (Daniel and 
Kottra, 2004).  In a recent study, the use of PhT1 knockout mice has demonstrated that 
PhT1 plays a significant role in transporting L-histidine into brain tissue, and potentially 
aiding in histamine homeostasis (Wang et. al, 2017).  PhT1 is predominantly expressed 
in the brain and eye (Yamashita et. al, 1997) while PhT2 is expressed in the lymphatic 
system and faintly in the brain (Sakata et. al, 2001).  Interestingly, it has been found that 
while PepT2 protein expression is present in the brain tissue of neonate mice, as they 
mature, PhT2 expression becomes more prominent (Hu et. al, 2014).  
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2.3 Proton-Coupled Oligopeptide Transporter 1 (PepT1) 
 
 
2.3.1 Structure/Function of PepT1   
            
            Currently the consensus on PepT1 structure, validated by hydropathy plots and 
epitope-tagging, is that this transporter contains 12 transmembrane (TM) helices, has 
both the C and N-terminus facing in toward the cytoplasm, and exhibits a large 
extracellular loop between H9 and H10 (Smith, et al., 2013; Rubio-Aliaga and Daniel, 
2002).  PepT1 is also known to undergo extensive glycosylation, particularly at this loop 
(Covitz et. al, 1998).  Additionally, in mice and humans, putative sites for protein kinase 
C-dependent phosphorylation have been identified (Liang et. al, 1995; Fei et. al, 2000). 
The membrane topology of PepT1 is illustrated in Figure 2.1. 
  An advanced structural understanding of PepT1 has largely been derived from 
crystalline studies on similar bacterial peptide transporters (PTRs).  In 2011, Newstead 
et al. elucidated the crystal structure of the prokaryotic homologue PepTso from 
bacterium Shewanella oneidensis with a resolution of 3.6 angstroms.  The structure 
revealed a 14 TM domain “V-shaped” protein in a ligand-bound occluded state.  The 
binding site includes residues from eight helices: 1, 2, 4, 5, 7, 8, 10, and 11. With 
roughly a 30% transmembrane identity to the mammalian PepT1, the researchers found 
that many residues with suspected key functional activity in PepT1 are conserved in this 
protein as well (Newstead et. al, 2011).  In addition, the crystalized structure PepTST 
from Streptococus thermophiles was studied in the ligand-free open state (Solcan et. al, 
2012), while GkPOT from Geobacillus kaustophilus and PepTSo2 from Shewanella 
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oneidensis were both studied in the ligand-bound open state (Doki et. al, 2013; Guettou 
et. al, 2013).     
   While no crystal structure has yet to be determined for mammalian PepT1, a 
review article has addressed the information gleaned from these crystal structure 
studies to propose a general mechanism for proton-coupled peptide transporters as 
illustrated in Figure 2.2. The main idea is that the transporter goes from an outward 
open state where an extracellular proton and peptide enters the binding pocket, to a 
peptide bound occluded state, and finally to an outward bound state where the two 
substrates are released inside the cell. While in the outward open state the proton is 
thought to bind to a conserved glutamate. This, in turn, facilitates the binding of the 
incoming peptide in which its specificity is modulated by conserved tyrosine residues.  
Movement from the outward to inward open state involves hinge-like action from select 
transmembrane regions coupled with salt bridge formation and disassociation 
(Newstead, 2015).  
 
2.3.2 Cellular Transport Mechanism of PepT1 
 
 
 
In 1983, researchers began to uncover the transport mechanism of dipeptide 
transfer.  Ganapathy and Leibach (1983) found that dipeptide transfer across intestinal 
and renal brush-border membrane vesicles was mediated by an inward flux of protons. 
Further experiments involving the two-electrode voltage clamp (TEVC) technique 
confirmed this electrogenic process, by recording electric currents from oocytes 
expressing human and rabbit PepT1.  Additionally, this study design revealed that 
9 
 
substrate transport via PepT1 follows Michaelis-Menten kinetics (Nussberger et. al, 
1997; Mackenzie et. al, 1996; Amasheh et. al, 1996; Kottra et. al, 2002).  Interestingly, 
proton to substrate transfer ratios for neutral, acidic, and basic substrates were found to 
be 1:1, 2:1, and 1:1, respectively (Steel et. al, 1997).  In pH-dependent studies, Lister 
et. al (1997) discovered that anionic dipeptide transport activity increases after a 
corresponding drop in luminal pH, while cationic dipeptide transport activity increases 
under more alkaline conditions. 
The mechanistic understanding of peptide and peptidomimetic transport from the 
lumen to the blood can be visualized on the cellular level (Figure 2.3).  First, peptides 
and peptidomimetic compounds from the lumen of the small intestine must be 
transferred across the apical membrane by the action of the PepT1 transporter.  Once 
within the enterocyte, enzymes may then metabolize these compounds.  These 
metabolic products and/or their parent compounds can then be transported into the 
bloodstream through the basolateral membrane by utilizing transporters (such as amino 
acid or efflux) or by passive diffusion (Rubio-Aliaga and Daniel, 2002; Brandsch, 2013). 
In order to have effective peptide transport, the proton gradient needs to be 
maintained across the cell surface.  The Na+-H+ exchanger NHE3 located on the apical 
brush border membrane is thought to be a key player in this regard, with the ability to 
export protons out of the enterocyte. However, since proton transport is coupled to 
sodium its transport activity hinges on the basolateral Na+/K+-ATPase maintaining 
intracellular sodium balance (Thwaites and Anderson, 2007). 
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2.3.3 Substrate Specificity of PepT1 
 
It is well established that PepT1 has wide substrate specificity.  Up to 400 
dipeptides and 8000 tripeptides from the 20 proteinogenic amino acids, as well as 
number of peptidomimetics like β-lactam antibiotics, angiotensin-converting enzyme 
(ACE) inhibitors, and numerous prodrugs are known to be transported by PepT1 
(Rubio-Aliaga and Daniel, 2002; Brandsch et al., 2013).  Undoubtedly, notable 
exceptions to substrate recognition and transport do exist.  For example, dipeptides that 
consist of two basic residues and those that contain a proline at the N-terminus and a 
hydrophobic residue at the C-terminus demonstrate low or no transporter activity 
(Balvinder et al., 2006).  
General guidelines have been established for ideal substrates such as: a) 
zwitterionic molecules are favored over those substrates with net charge; b) the peptide 
bond can be replaced with a ketomethylene bond (i.e. δ-aminolevulinic acid) or acid 
amide bond; c) a peptide bond must be in the trans-conformation; d) the NH3+ and 
carbonyl group are needed for high affinity transport; e) the COO- group is not 
necessarily needed and can be switched with phosphoric acid or arylamide groups; e) 
there is stereoselectivity for L-isomer peptides; and f) affinity is improved with greater 
hydrophobicity (Brandsch et al., 2004; Brandsch et al., 2013). 
 
 
2.3.4 Localization and expression of PepT1 
 
 
 
It has been conclusively demonstrated that, in rats, humans and mice, PepT1 is  
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highly expressed at the apical side of enterocytes lining the small intestine. Protein  
 
and/or mRNA levels have been recorded at different segments along the  
 
gastrointestinal tract, with the duodenum, jejunum, and ileum having notable expression  
 
over the low/non-existent levels in the colon (Ogihara et al., 1996; Walker et al., 1998;  
 
Groneberg et al., 2001; Jappar et al., 2010).  In particular, Japper et. al (2010) found   
 
that in wildtype mice, PepT1 transcript expression was highest in the jejunum, followed  
 
by ileum, distal colon, duodenum, and with no noticeable expression in the proximal  
 
colon.  The protein expression levels, meanwhile, were highest in jejunum, intermediate  
 
in the other segments of the small intestine, and absent in both distal and proximal  
 
colon.  Another study, however, conflicts with this finding by asserting that PepT1  
 
protein levels are low but present in the distal colonic tissue of mice (Wuensch et al.,  
 
2013).    
  
A study by Drozdzik et al., (2014) highlights the relative abundance of PepT1 in  
 
human small and large intestines.  This was achieved by quantifying the protein levels  
 
of nine commonly expressed intestinal transporters derived from the tissue of Polish  
 
donors. These researchers found that 50% of the transporter protein in the small  
 
intestine was attributed to PepT1, but the same transporter was much less abundant  
 
(5%) in the colon.  
 
PepT1 is also expressed at lower levels in the early proximal tubules of the  
 
kidneys, the apical side of epithelial cells lining the bile duct, the liver, in lysosomes of  
 
the acinar cells of the pancreas, and the placenta (Doring et al., 1998; Herrera-Ruiz et  
 
al., 2001; Knütter et al., 2002; Smith et al., 1998; Bockman et al., 1997). 
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2.3.5 Regulation of PepT1 
 
 
Since PepT1 plays a key role in the transport of therapeutically relevant 
peptidomimetics, it is important to understand the various mechanisms by which this 
transporter is regulated and controlled.  PepT1 expression and functional activity has 
shown to be influenced by hormones, drugs, physiological and pathological conditions, 
and developmental stage.  
Hormones such as insulin, leptin, and thyroid hormone play an important role in 
PepT1 regulation as determined in Caco-2 cell lines.  Insulin and leptin hormones were 
shown to increase the recruitment of PepT1 to the brush border membrane while mRNA 
levels remain constant.  This effectively increases the Vmax of PepT1 substrates, while 
the Km parameter remains unchanged.  Thyroid hormone, on the other hand, was shown 
to decrease PepT1 membrane density, thus decreasing Vmax. (Sun et. al, 2003; Buyse 
et. al, 2001; Ashida et. al, 2002).   
Pharmacological agents are also known to influence PepT1 regulation. 
Immunosuppressive compounds cyclosporine A and tacrolimus decrease PepT1 activity 
(Bugliani et. al, 2009), while pentazocine increases its uptake capacity (Fujita et. al, 
1999).  In another study, the authors found that four different Ca2+ channel blockers all 
increase the transport capacity of PepT1.  They propose these blockers stimulate the 
NHE3 indirectly and thus create a steeper gradient for proton-coupled transfer (Wenzel 
et. al, 2002). 
Diet has also been found to be a key regulator of PepT1.  A high protein diet in 
rats has been found to aid the up-regulation of the transporter, thus increasing its 
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activity (Erickson et. al, 1995; Shiraga et. al, 1999).  Conversely, fasting rats for one day 
also resulted in a greater transport capacity (Thamotharan et. al, 1999).  Ma et. al 
(2012) elaborated on the topic by comparing data between fasted and fed mice.  They 
observed that after 16 hours of fasting from a standard diet that these mice exhibited 
greater protein expression along with a significantly greater in vivo absorption of the 
PepT1 substrate Gly-Sar.   Additionally, expression patterns were shown to exhibit a 
diurnal rhythm with food intake (Zucchelli et. al, 2009). 
Physiological factors also contribute to PepT1 regulation.  A developmental study 
in rats showed that PepT1 protein expression in the small intestine increased sharply to 
a maximal value by 3-5 days after birth, dropped, then rose to 59-88% of the maximal 
value at the time of weaning.  By day 75, adult rats showed expression at 70% of the 
maximal value. Colonic expression was not detected after 5 days from birth (Shen et. al, 
2001). 
Interestingly, patients with ulcerative colitis and Crohn’s disease have shown 
colonic tissue that aberrantly expresses PepT1, where otherwise expression is minimal 
in healthy patients (Zucchelli et. al, 2009; Merlin et. al, 2001). However, these findings 
are in stark contrast to a newer study that determined mice induced with IBD and 
human tissue extracted from IBD patients show reduced PepT1 expression in the ileum 
and colon (Wuensch et al., 2014). 
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2.4 Rational Prodrug Design 
 
 
 Many attempts have been made by scientists to improve the oral bioavailability of 
various drugs. This has partly been achieved by placing emphasis on improving 
intestinal absorption, a major barrier to systemic exposure.  At first the common 
approach was to increase the lipophilicity of hydrophilic drugs in order to improve their 
passive diffusion through the lipid bilayer.  This prodrug approach involved linking lipid-
soluble moieties to the parent drug.  However, as lipophilic xenobiotics began to 
demonstrate their propensity for cellular toxicity interest shifted to hydrophilic prodrugs.  
These compounds, although limited by passive diffusion, can enhance intestinal 
absorption when an attached moiety can confer carrier-mediated uptake upon the 
parent drug (Steffansen et. al, 2004; Varma et. al, 2010).  
Other issues must also be considered when improving the bioavailability of 
prodrugs.  The chemical and enzymatic stability of prodrugs must be favorable for 
transport and delivery.  Many digestive enzymes are present in the gut lumen that may 
hydrolyze chemically labile bonds. Since these bonds link promoieties to their parent 
drugs, premature cleavage will undoubtedly decrease systemic exposure.  However, 
these bonds must not be so chemically and enzymatically stable as to greatly prevent 
cleavage once the prodrug has traversed the epithelial barrier and entered the 
bloodstream.  Additionally, efflux transporters located in the enterocytes may be 
problematic if they recognize either the prodrug or parent compound as a substrate and 
subsequently pumps it back out into the gut lumen (Yanni et. al, 2007). 
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2.5 The Prodrug Valacyclovir and Its Parent Compound Acyclovir 
 
 
 
2.5.1 Mechanism of Action 
 
 
          
          Valacyclovir, the L-valyl ester prodrug of acyclovir, is clinically used to treat 
patients with genital herpes and herpes zoster (Figure 2.4).   Acyclovir, as the 
therapeutic agent, serves as a nucleoside analog once cleaved from its promoiety.  
First, acyclovir enters infected cells where virally-generated thymidine kinases 
phosphorylate the compound to the mono-phosphate form.   After a series of additional 
phosphorylation steps, the triphosphate form binds to viral DNA polymerase and is then 
incorporated into the growing DNA strand.  The addition of this analog causes DNA 
synthesis to halt in its tracks (Baker et. al, 2002; Gnann et. al, 1983).   
 
 
2.5.2 Valacyclovir as a substrate for PepT1 
 
 
            
          Numerous cell culture studies have highlighted the significance of hPepT1 in 
mediating the uptake of valacyclovir (Table 2).  Valacyclovir transport in transfected 
cells (i.e. Xenopus laevis oocytes, Caco-2, CHO, and MDCK) all followed Michaelis-
Menton kinetics with Km values ranging from 0.29 to 5.94 mM.   Notably, a 
comprehensive study by Balimane and Sinko (2000) explored the effect of pH and 
ionization states on the hPepT1-mediated uptake of valacyclovir in CHO cells.  They 
found that the uptake of valacyclovir was greatest at pH 7.4.  This was attributed to the 
16 
 
higher percentage of neutral species, which exhibited the highest affinity for transport 
(i.e. Km of 1.2 mM for neutral species versus 7.4 mM for cationic species). 
 Consequently, valacyclovir was also found to be a substrate for other intestinal 
transporters as well.  Gly-Sar actively inhibited valacyclovir uptake in SKPT cells 
expressing rat PepT2 (Ganapathy et. al, 1998).  The organic anion transporter 3 (OAT3) 
contributed to valacyclovir uptake in S2 cells with an estimated Km of 57.9 μM and a 
Vmax of 200 pmol/mg protein/minute (Takeda et. al, 2002).  The ATB0,+ transporter, 
which is abundantly expressed on the luminal surface of colonic tissue, demonstrated 
valacyclovir uptake through inhibition in HRPE cells (Hatanaka et. al, 2004).  Moreover, 
COS-7 cells expressing hPhT1 showed significantly greater uptake for valacyclovir over 
mock cells at pH 5.0 (Bhardwaj et. al, 2006).  A noteworthy experiment done by 
Landowski et. al (2003) found that HeLa cells expressing HPT1 also transports 
valacyclovir. This study was conducted because Landowski and coworkers found a 
positive correlation between HPT expression in human duodenum and systemic 
exposure of acyclovir after oral dosing of valacyclovir.  Interestingly, they claim that no 
such correlation was found to exist for the PepT1 transporter. 
          In response to the various in vitro studies attempting to attribute PepT1 or another 
intestinal transporter to valacyclovir uptake, Yang and Smith (2013) sought to uncover 
the significance and contribution of PepT1-mediated transport with mice.  By measuring 
permeability values (via perfusions) in both wildtype and PepT1 knockout mice, the 
contribution of the PepT1 transporter was found to be greater than 80%.  The knockout 
mice only had permeability values approximately 10% of that seen in wildtype.  The Km 
for valacyclovir was reported as 10.2 mM.  Inhibition studies ruled out ATB0,+, PhT1/2, 
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OATs, and OCTs as significant contributors to uptake.  Subsequent oral administration 
studies corroborated their findings. 
 
 
2.5.3 Hydrolysis of Valacyclovir 
          
 
          Valacyclovir is predisposed to hydrolysis due to its labile ester bond.  Granero 
and Amidon (2006) investigated the stability of this compound in buffers and 
gastrointestinal fluids derived from different species.  These authors made the following 
conclusions: 1) valacyclovir undergoes base-catalyzed pseudo-first order kinetics; 2) it 
has suitable stability under pH 4; and 3) the prodrug is more stable in buffer than in 
intestinal fluid of the same pH.  Moreover, there is solid evidence to support the notion 
that valacyclovir hydrolysis is rapid and nearly complete in vivo. For example, after the 
oral administration of valacyclovir in humans, more than 99% of the absorbed prodrug 
was converted to acyclovir (Soul-Lawton et. al, 1995). Additionally, a similar study 
showed the valacyclovir-to-acyclovir Cmax ratio to be minimal (i.e. 4%) following 
administration (Weller et. al, 1993).  Rapid and complete hydrolysis has also been 
extended to mice, as demonstrated in studies by Yang and Smith (2013). 
          Esterases responsible for prodrug hydrolysis are primarily expressed in three 
regions: on the luminal surface, within intestinal enterocytes, and in the liver 
(MacDougall and Guglielmo, 2004).  Many researchers have attempted to determine the 
specific enzyme(s) that activate valacycloivir.  In 1995, Burnette and coworkers isolated 
and characterized an enzyme in rat that specifically hydrolyzes valacyclovir.  Years 
later, the human valacyclovirase, biphenyl hydrolase-like protein (BPHL) was also 
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identified and characterized from Caco-2 cells.  This enzyme was found to hydrolyze 
valacyclovir with a specificity constant of 420 mM-1-s-1 (kcat/Km) (Kim et. al, 2003).  
However, a recent study was conducted seeking to understand the impact of BPHL on 
the hydrolysis of valacyclovir in mice.  After the oral administration of valacyclovir in 
wildtype and BPHL knockout mice, it was determined that the AUC ratio of valacyclovir 
to acyclovir was 5.5% and 9.1% for wildtype and BPHL knockout mice respectively.  
Finding only a marginal reduction in the hydrolase activity of valacyclovir in BPHL KO 
mice, the authors concluded that this enzyme is not essential for prodrug activation (Hu 
et. al, 2018). 
 
 
2.5.4 Pharmacokinetics of Valacyclovir and Its Parent Compound Acyclovir 
 
 
 
          The bioavailability of acyclovir in humans was reported as 54.2% after the oral 
administration of 1000 mg valacyclovir (Soul-Lawton et. al, 1995).  In contrast, 
bioavailability was observed to only be 15-30% when acyclovir was administered 
instead (Laskin, 1983).  This is commonly attributed to its poor intestinal permeability.  
PepT1 does not transport acyclovir (Han et. al, 1998), but instead undergoes passive 
absorption (Meadows and Dressman, 1990).  Acyclovir distributes well into tissues 
including the CSF (~50% of plasma levels), with protein binding found to be 15% in 
patients (MacDougall and Guglielmo, 2004).  An in vitro study showed acyclovir to bind 
in mouse plasma at 14% and in human plasma at 22-33% (de Miranda et. al, 1981).    
          In clinical trials acyclovir was administered intravenously with doses that ranged 
from 2.5-15 mg/kg.  Elimination of acyclovir followed a two-compartment model with a 
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terminal half-life of 2-3 hours.  Dose proportionally was observed in respect to Cmax and 
AUC values.  Renal contribution to clearance was approximately 77% of total clearance 
with tubular secretion and filtration both contributing to renal drug excretion (Whitley et. 
al, 1982; Laskin et. al, 1982).  In terms of metabolism 9-carboxymethoxymethylguanine 
(CMMG) comprised 8.5-14.1% of the total administered dose in humans, with >.5% 
being 8-OHACV (Soul-Lawton et. al, 1995).  Metabolites excreted from mice constituted 
4% of the dose (de Miranda et. al, 1981). 
          In a pivotal study from Yang et. al (2013), the pharmacokinetic features of 
acyclovir were determined after the oral administration of valacyclovir in wildtype and 
PepT1 knockout mice.  AUC0-180 and Cmax decreased substantially in the PepT1 
knockout mice across four doses: 10, 25, 50, and 100 nmol/g.  Oral dose escalation 
revealed that both Cmax and AUC increase linearly with dose in wildtype and knockout 
mice.  Intravenous acyclovir concentration-time profiles were similar across genotypes, 
indicating absorption is the main driver for differences in valacyclovir pharmacokinetics. 
Tissue to blood ratios were not significantly different between genotypes.   
          In contrast to the aforementioned studies in mice, some clinical research has 
showcased non-linear pharmacokinetics for acyclovir following orally administered 
valacyclovir.  Weller et. al (1993) found less than proportional increases in the Cmax and 
AUC of acyclovir in single-dose studies ranging from 100-1000 mg, as well as from 
multiple-dose (i.e. QID for 11 days) studies ranging from 250-2000 mg. In particular, 
they determined from their single-dose escalation studies that Cmax increased from 0.83 
to 5.65 mg /L, while AUC increased from 2.28 to 19.52 mg/L*hr.  A similar clinical study 
reported by Jacobson (1993) discovered only a non-linear trend for AUC values, while a 
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third clinical study by Ormrod et. al (2000) found linear trends for both Cmax and AUC 
over the dose range of 100-1000 mg. 
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2.6 Issues with Predicting Clinical Pharmacokinetics: In Vitro  
 
Scaling and Interspecies Differences 
  
 
 
Currently, two approaches attempt to predict the clinical pharmacokinetic 
parameters from ADME processes in animals.  One approach involves the use of 
physiological modeling with in vitro data (Kang and Lee, 2011).  In a particular case, 
Hallifax et. al (2010) compiled data with this method and found intrinsic clearance in 
cryogenic hepatocytes consistently under-predicts intrinsic clearance in vivo.  While this 
situation can be corrected empirically, the scenario illustrates a lack of knowledge in the 
mechanistic details attributing to the miscorrelation.  The authors suggest differences 
may be due to reduced enzymatic activity or lower permeability in these hepatocytes.  
The second approach, which is more commonly utilized, involves allometric 
scaling. This method often involves the use of three animals models in which 
pharmacokinetic and physiological parameters are acquired for each species.  After a 
regression analysis is conducted, human pharmacokinetic parameters are extrapolated 
from the data (Polekhina et. al, 2014). Although success can sometimes be achieved, at 
other times animal models can fail to properly predict clinical values.  Thus, commonly 
used measures of allometric scaling success (e.g., correlation coefficient and allometric 
exponent) failed to discriminate between successful and failed allometric predictions 
(Ward and Smith, 2004).  
The challenges faced by allometric scaling can certainly be due to species 
differences in the functional activity of intestinal transporters.  As previously mentioned, 
clinically administered valacyclovir has demonstrated less than proportional increases in 
AUC and Cmax with increasing oral dose.  Yet, Yang and Smith (2013) found that 
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comparable doses in mice yielded linear pharmacokinetics.  These differences are 
thought to be chiefly due to the fact hPepT1-mediated intestinal transport is saturated at 
high doses.  Thus, it is quite possible to over-predict clinical values if wildtype mice are 
utilized in interspecies scaling.  However, what could be the mechanistic reason behind 
these differences?  Yang and Smith (2013) believed these differences were due to the 
mouse PepT1 and human PepT1 transporters having different affinities for the 
substrate.  This assertion was well founded.  In a novel study, human, mouse, and rat 
PepT1 isoforms expressed in yeast P. Pastoris demonstrated distinct transport kinetics 
for the model dipeptide Gly-Sar. Specifically, the substrate affinity (Km) was found to be 
the following: 0.86 mM for human, 0.3 mM for mouse, and 0.16 mM for rat (Hu et. al, 
2012).    
PepT1 protein expression levels could also be different between species.  
Although no definitive study has been done to address protein levels, one research 
group found mRNA levels encoding transporters in the intestine to be quite different 
among mice, rats, and humans.  In particular, PepT1 mRNA transcripts in clinical tissue 
were approximately 2-fold and 6-fold lower than what was found in mice and rats, 
respectively (Kim et. al, 2007).  As for expression in the kidney, mRNA levels were 
moderate in the rat but low in the mouse (Lu and Klaassen, 2006).  
 
 
 
 
 
 
 
 
 
 
23 
 
2.7 Humanized Pept1 Mice 
 
 
 
 In an attempt to mitigate the interspecies differences observed following 
valacyclovir and cefadroxil administration in mice and humans (Yang et. al, 2013; Weller 
et. al, 1993; Posada and Smith, 2013; Garrigues et. al, 1991), Hu et. al (2014) 
generated the humanized PepT1 (huPepT1) transgenic mouse model. The 
development of these mice involved the insertion of the huPepT1 gene (with both 
coding and regulatory elements) into a one-celled embryo with a PepT1-/- background.   
Once generated, these mice needed to be fully validated. A full phenotypic 
analysis was conducted and the results were found to be normal.  mRNA expression 
studies demonstrated that huPepT1 mice had measureable levels in every segment of 
the small intestine but lower expression in the large intestine.  Similarly, protein 
expression studies revealed high levels in the small intestine but trace levels in colonic 
tissue.  No measurable PepT1 was found in the kidney. Additionally, other transporter 
genes were monitored to check for potential compensatory changes in huPepT1 mice, 
with wildtype acting as a baseline.  Most notably, mPat1 transcripts in the small intestine 
and mOat transcripts in the kidney increased by approximately 2-fold in huPepT1 mice.  
Lastly, functional activity for huPepT1-meditated transport was assessed in these mice 
by conducting intestinal perfusion studies with Gly-Sar.  The uptake of this substrate 
exhibited Michaelis-Menton kinetics in wildtype and huPepT1 mice, with Vmax values of 
3.75 and 0.5 nmol/cm2/sec, respectively, and Km values of 13.2 and 3.3 mM, 
respectively (Hu et. al, 2014). 
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More recently, the intestinal permeability and oral absorption of cefadroxil was 
evaluated in both wildtype and huPepT1 transgenic mice.  Following segment-
dependent studies, it was determined that small intestinal permeability in huPepT1 mice 
was only 50-60% of wildtype values, and that colonic permeability was 14-fold higher in 
the humanized transgenic mice.  Furthermore, concentration-dependent studies 
revealed that the Km and Vmax of transport in huPepT1 mice (as compared to wildtype) 
were approximately 2-fold and 7-fold lower, respectively.  Subsequently, IV bolus 
administration studies determined that there were no differences in drug disposition for 
cefadroxil in wildtype and huPepT1 mice. However, oral dose escalation studies in 
huPepT1 mice revealed less than proportional increases in Cmax and AUC, while only 
linear trends were observed in wildtype.    These differences became compelling after 
huPepT1 mice were found to better match the trends and values derived from 
comparable clinical doses (Hu and Smith, 2016; Garrigues et. al, 1991).  
 
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
25 
 
2.8 The Cav1.3 Calcium Channel and Inhibition by the Dihydropyridine 
 
Nifedipine 
  
 
 
2.8.1 Introduction of Cav1.3 and Nifedipine 
 
 
 
In total, there are 10 calcium channel isoforms.  Each isoform is differentiated by  
 
a unique α1 subunit, which is the pore-forming structure of the channel.  Specifically,    
 
the Cav1.3 isoform belongs to the subclass of long lasting voltage-gated (L-type)  
 
calcium channels.  These Cav1.3 channels are expressed in many different tissues of  
 
the body.  They are prominently found in sinoatrial node cells where they help mediate  
 
pacemaking activity of the heart.  Additionally, these channels contribute to auditory  
 
transduction in the ear and endocrine secretion (Striessnig et. al, 2015; Catterall, 2011).  
 
Cav1.3 is also expressed in intestinal enterocytes.  A protein expression study in rats  
 
found these channels along the gastrointestinal tract with peak levels in the distal  
 
jejunum and proximal ileum (Morgan et. al, 2003).  Moreover, gene expression studies  
 
done with clinical and mouse intestinal tissue revealed the presence of Ca v1.3  
 
transcripts in all segments of the small and large intestine. It is important to note that in  
 
mice, transcript levels were found to be much greater in the colon than in the small  
 
intestine (Radhakrishnan et. al, 2016; Reyes-Fernandez and Fleet, 2015). 
 
 As depicted in Figure 2.5, there are primarily three routes that can initiate   
 
calcium transport from the lumen to the blood. Uptake can occur through the tight  
 
junctions, the vitamin D dependent calcium channel TRPV6, or the calcium channel  
 
Cav1.3.  The relative contribution of the paracellular and transcellular routes for calcium  
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flux is seemingly contentious (Kellett, 2011; Radhakrishnan et. al, 2016). On the other  
 
hand, TRPV6 and Cav1.3 transport are proposed to work in complementary ways.    
 
Under depolarizing conditions the Cav1.3 channel should be more active than the  
 
TRPV6 channel, while under hyperpolarizing conditions the inverse should be true.   
 
Depolarization across the intestinal enterocyte occurs via nutrient uptake, like when  
 
glucose and Na+ ions are transported by SGLT1 (Kellett, 2011).  In fact, the co- 
 
perfusion of 10 μM nifedipine and 20 mM glucose resulted in the inhibition of 78% of  
 
total calcium uptake, while the  perfusion of nifedipine alone dropped total inhibition to  
 
52%.   
 
The dihydropyridine nifedipine is commonly administered to patients with angina  
 
or hypertension.  The compound behaves as an arterial vasodilator by binding to L-type  
 
calcium channels and preventing calcium influx into smooth muscle cells (Snider et. al,  
 
2008).  Furthermore, nifedipine is a highly potent compound that was shown to block  
 
50% of the Cav1.3 channels at a concentration of 20.1 nM in tsa201 cells (Sinnegger- 
 
Brauns et. al, 2009).  However, the perfusion of 1 μM nifedipine though a segment of rat  
 
jejunum was determined to be insufficient at blocking calcium influx.  This changed  
 
when the concentration was elevated to 10 μM, as calcium influx was then blocked by  
 
73% (Morgan et. al, 2003).  In contrast, another study found that nifedipine did not  
 
appear to have an effect on calcium absorption in rat duodenum, unlike verapamil at  
 
concentrations higher than 1 mM (Fox and Green, 1986). The rat duodenum, though, is  
 
known to express relatively low levels of Cav1.3 (Morgan et. al, 2003).  This fact may  
 
perhaps diminish the value of this study. 
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2.8.2 Proposed mechanism of nifedipine and its effect on PepT1 activity 
 
 
 
A proposed mechanism that links nifedipine administration to the increased  
 
functional activity of PepT1, and for which is largely supported in the work by Wenzel et.  
 
al (2002), is illustrated in Figure 2.6.  First, nifedipine binds to the Cav1.3 channel and  
 
blocks calcium influx into the enterocyte. This would then result in the decreased activity  
 
of other transporters reliant on calcium like the basolateral Na+/Ca+ (Barboza et. al,  
 
2015).  An imbalance in sodium may then enhance the activity of the NHE3 transporter.   
 
In turn, the increase in proton efflux would effectively provide a larger gradient for  
 
PepT1-mediated transport.   However, there is some doubt about the role of the NHE3  
 
transporter and its ability to modulate PepT1-mediated transport.  In a clinical study  
 
involving the oral administration of cefadroxil and tenapanor (a NHE3 inhibitor), the  
 
researchers observed that cefadroxil pharmacokinetics remain unchanged in the  
 
presence of this other drug (Johansson et. al, 2017). 
 
 Another mechanism was also proposed for the drug-drug interaction involving  
 
nifedipine and PepT1 substrates.  It was suggested that the calcium-blocking effects of  
 
nifedipine would modulate the activity of the enteric nervous system, and thus affect the  
 
activity of PepT1. A series of rat intestinal perfusion studies investigated this  
 
premise (Harcouet et. al, 1997; Berlioz et. al, 1999).   However, the enhancement of  
 
cefixime uptake in CaCo2 cells, while in the presence of nifedipine and other blockers,  
 
refutes this neuron-centric mechanism (Wenzel et. al, 2002).  Additionally, no studies  
 
on the impact of the enteric nervous system were ever carried out in vivo, as noted by  
 
Wenzel et. al (2002).  In a more positive light, some interesting insights have come out  
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of these aforementioned intestinal perfusion studies as related to the impact of  
 
nifedipine, including:  1) the enhancement of PepT1 absorption was not due to any  
 
hemodynamic effect; and 2) there were no changes to gastric motility (Harcouet et. al,  
 
1997). 
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2.9 Interaction Studies Involving Nifedipine and Pept1 Substrates 
 
 
 
 Many studies have investigated and found significant drug-drug interactions  
 
(DDIs) involving nifedipine and various PepT1 substrates (Table 2.2).  Notably, two of  
 
these studies were clinically focused.  The first study involved the oral administration of  
 
1 gram amoxicillin either alone or 30 minutes after the oral administration of 20 mg  
 
nifedipine.  It was determined that in the presence of nifedipine the following  
 
pharmacokinetic parameters changed for amoxicillin: a 22% increase in AUC, a 21%  
 
increase in bioavailability, a 15% increase in Cmax, and a 21% decrease in Tmax.   
 
However, there were no changes in the volume of distribution or clearance for this  
 
compound.  Thus, the authors concluded that nifedipine enhanced the oral absorption of  
 
amoxicillin (Westphal et. al, 1990).  In a similar clinical study 200 mg of cefixime was  
 
orally administered alone or 30 minutes after the oral administration of 20 mg nifedipine.   
 
Again, the following pharmacokinetic parameters changed for cefixime while in the  
 
presence of nifedipine: a 46% increase in Cmax, a 69% increase in AUCext, and a 71%  
 
increase in bioavailability.  In addition, a deconvolution analysis revealed that 50% of  
 
the total dose was absorbed in the presence of nifedipine, but was markedly lower,  
 
namely 30%, when nifedipine was absent.  Coupling these results with the knowledge  
 
that no changes to drug disposition occurred, the authors concluded that nifedipine  
 
enhanced the oral absorption of cefixime (Duverne et. al, 1992). 
 
 Three DDI studies were conducted in rats.  In the first study, rats were orally  
 
administered 22.4 mg/kg cephalexin either alone or 30 minutes after the oral  
 
administration of 10 mg/kg nifedipine.   In the presence of nifedipine, cephalexin 
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bioavailability increased 23%, the Cmax increased 57%, the AUC increased 34%, and the  
 
T0.5 and Tmax remained unchanged.  The authors concluded, as with the clinical studies,  
 
that nifedipine enhanced the oral absorption of this PepT1 substrate (Berlioz, et. al,  
 
2000). As for the other two studies, these involved in situ intestinal perfusions of  
 
cephalexin or cefixime ± nifedipine through the small intestine.  Specifically, nifedipine  
 
or a drug-free solution was perfused for 15 minutes.  This was then followed by the  
 
perfusion of 1 mM of cephalexin or cefixime for 60 minutes.  Upon completion of the  
 
intestinal perfusions, the plasma concentrations of both cephalexin and cefixime were  
 
both at least 2-fold greater in the presence of nifedipine. These increases were again  
 
attributed to the enhancement of intestinal absorption (Berlioz et. al, 1999; Harcouet et.  
 
al, 1997).  However, these same researchers claim that nifedipine did not enhance  
 
cefixime uptake in previously conducted in vitro studies.  This is in contrast to the  
 
comprehensive study by Wenzel et. al (2002), where they observed a nearly 2-fold  
 
increase in the Caco-2 cell permeability of cefixime in the presence of nifedipine. 
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2.10 Figures and Tables 
 
 
 
 
 
 
 
Figure 2.1 The membrane topology of PepT1. (Adopted from Rubio-Aliaga and Daniel, 
2002) 
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Figure 2.2 A general mechanism for peptide transport. (Adopted from Newstead, 2015) 
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Figure 2.3 An illustrative model showing PepT1-meditated uptake of dietary peptides in 
intestinal enterocytes. (Adopted from Smith et. al, 2013) 
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Figure 2.4 The chemical structures of acyclovir and valacyclovir.   
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Figure 2.5 Possible routes for calcium uptake in the intestinal enterocyte. (Adopted 
from Kellett, 2011) 
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Figure 2.6 A proposed mechanism that links nifedipine administration with an 
enhancement of PepT1-mediated transport for valacyclovir (VACV).  The steps for the 
mechanism are as follows: (1) NFP inhibits Cav1.3 at the apical membrane; (2) reduced 
intracellular Ca2+ attenuates Ca2+/Na+ exchange at the basolateral membrane; (3) 
reduced intracellular Na+ stimulates NHE3 at the apical membrane; and (4) PepT1 
activity is stimulated by the increased proton gradient at the apical membrane.   
 
 
 
 
 
 
 
 
 
 
 
 
(1) 
(2) 
(3) (4) 
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Table 2.1 Various uptake studies performed with valacyclovir in cells transfected with 
hPepT1.   
 
Cell line pH of uptake 
buffer 
Km (mM) Vmax (Various 
Units) 
Reference 
Xenopus laevis 
oocytes 
5.5 5.94 1.68 
nmol/hr/oocyte 
 
Balimane et. al, 
1998 
CaCo2 7.4 0.292 15.7 nmol/h*cm2 
 
Han et. al, 1998 
CHO 7.5 1.64 23.34 nmol/mg 
 protein/5 min 
 
Guo et. al, 1999 
CHO 7.5 2.69 N/A Balimane and 
Sinko, 2000 
 
MDCK 6.0 5.05 5.88 nmol/mg 
protein 
 
Bhardwaj et. 
al ,2005 
CaCo2 6.0 1.55 2.93 nmol/mg 
protein 
Bhardwaj et. al, 
2005 
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Table 2.2 Various drug-drug interaction studies involving nifedipine and a PepT1 
substrate. 
 
 
Species/Cell 
culture 
Study Type Nifedipine 
Dose/conc. 
PepT1 
Substrate 
Buffer 
Solution 
DDI Result 
on PepT1 
substrate 
Reference 
Clinical Oral 
administration 
20 mg 200 mg 
cefixime 
Water 71% 
increase in 
bioavailability 
 
Duverne et. 
al, 1992 
Clinical Oral 
administration 
20 mg 1 gram 
amoxicillin 
Water 21% 
increase in 
bioavailability 
 
Westphal 
et. al, 1990 
CaCo2 Cell uptake 100 µM 1 mM 
cefixime 
Modified 
Krebs, pH 
5.0, 10 mM 
glucose 
 
Nearly 50% 
increase in 
uptake 
Wenzel et. 
al, 2002 
Rat Oral 
administration 
10 mg/kg 22.4 mg/kg 
cephalexin 
Krebs-
ringer, pH 
7.5 
23% 
increase in 
bioavailability 
 
Berlioz et. 
al, 2000 
Rat Jejunal 
perfusion 
100 µM 1 mM 
cephalexin 
Krebs-
ringer, pH 
7.5 
50% 
increase in 
plasma 
concentration 
 
Berlioz et. 
al, 1998 
Rat Duodenojejum 
perfusion 
100 µM 1.1 mM 
cefixime 
Krebs-
ringer, pH 
5.5, 9.2 mM 
citric acid 
76% 
increase in 
portal vein 
blood 
concentration 
Harcouet et. 
al, 1996 
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CHAPTER 3 
 
Evaluating the Intestinal and Oral Absorption of the Prodrug  
 
Valacyclovir in Wildtype and Hupept1 Transgenic Mice 
 
 
 
3.1 Abstract 
 
 
The purpose of this work was to evaluate the intestinal permeability, oral 
absorption and disposition of the ester prodrug valacyclovir in wildtype mice and a 
huPepT1 transgenic mouse model. PepT1 (SLC15A1) is a transporter apically 
expressed along the epithelial cells of the gastrointestinal tract and is responsible for the 
absorption of di-/tripeptides, ACE inhibitors, β-lactam antibiotics and numerous 
prodrugs. Unfortunately, PepT1-mediated substrates that have been extensively studied 
were shown to exhibit species-dependent absorption and pharmacokinetics. 
Accordingly, in situ intestinal perfusion studies were conducted and valacyclovir uptake 
was shown to have a 30-fold lower Km and 100-fold lower Vmax in huPepT1 compared to 
wildtype mice.  Moreover, inhibition studies demonstrated that the huPepT1 transporter 
alone was responsible for valacyclovir uptake, and segment-dependent studies reported 
significant reductions in permeability along the length of small intestine in huPepT1 
mice.  Subsequent oral administration studies revealed that the in vivo rate and extent 
of valacyclovir absorption were lower in huPepT1 mice, as indicated by 3-fold lower 
Cmax and 3-fold higher Tmax values, and an AUC0-180 that was 80% of that observed in 
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wildtype mice. However, no significant changes in drug disposition were observed 
between genotypes after intravenous bolus administration of acyclovir. Lastly, mass 
balance studies established that the bioavailability of acyclovir, after oral dosing of 
valacyclovir, was 77.5% in wildtype mice and 52.8% in huPepT1 mice, which 
corroborated values of 51.3% in clinical studies. Thus, it appears the huPepT1 
transgenic mice may be a better model to study prodrug absorption and disposition in 
humans than wildtype mice.  
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3.2 Introduction 
 
 
The proton-coupled oligopeptide transporter PepT1 (SLC15A1), which is expressed 
along the apical side of intestinal enterocytes, has become a prime target for prodrug 
binding and uptake. A prodrug is similar in structure to a pharmacologically active 
parent compound but contains an added chemical promoiety that, in this case, confers 
PepT1-mediated transport upon the entire molecule, thus enhancing intestinal 
absorption (Rubio-Aliaga and Daniel, 2002; Dahan et. al, 2014). One reason PepT1 has 
become a preferential target is because of this transporter’s abundant expression along 
the gastrointestinal tract. This fact is substantiated in a study by Drozdzik et. al (2014), 
showing that relative PepT1 protein expression in the human small intestine constitutes 
half of all tested transporter proteins.  Secondly, PepT1 is targeted due to its high 
capacity transport and broad substrate specificity.  Known substrates to be transported 
by PepT1 include di/tripeptides, peptidomimetic compounds such as β-lactam antibiotics 
and ACE inhibitors, and a growing number of prodrugs (e.g. valacyclovir, valganciclovir, 
L-dopa-L-Phe, and zanamivir) (Rubio-Aliaga and Daniel, 2002; Dahan et. al, 2014; 
Brandsch et. al, 2013; Sugawara et. al, 2000).  
 Valacyclovir is the L-valine prodrug of acyclovir, a nucleoside antiviral that is used 
for the treatment of genital herpes and herpes zoster (Baker et. al, 2002).  Importantly, 
this compound has been studied extensively as a substrate for PepT1-mediated 
transport.  In a novel study by Yang and Smith (2013), the authors found that PepT1 
contributed >80% of the in situ intestinal permeability of valacyclovir in wildtype mice 
and, in a subsequent study by Yang et. al (2013), they observed a substantially greater 
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oral absorption of valacyclovir as compared to PepT1 knockout mice.  Many in vitro 
studies have also demonstrated that cells transfected with human PepT1 exhibit 
functional activity for valacyclovir transport (Balimane et. al, 1998; Han et. al, 1998; Guo 
et. al, 1999; Balimane and Sinko, 2000; Bhardwaj et. al, 2005).    
 Although studies investigating PepT1-mediated uptake are numerous, a definitive 
species difference in PepT1 transporter kinetics was first reported in Pichia pastoris 
expressing the mouse, rat, and human orthologs (Hu et. al, 2012).  In light of this 
finding, Hu et. al (2014) developed a novel humanized transgenic mouse line (huPepT1) 
that was proven to be viable, express human PepT1 protein along the intestinal tract, 
and demonstrate functional activity with the model dipeptide glycylsarcosine.  More 
recently, these same researchers validated huPepT1 with the β-lactam antibiotic 
cefadroxil (Hu and Smith 2016).  The huPepT1 mice clearly showed a higher affinity 
(i.e., lower Km) and lower capacity for transport (i.e. lower Vmax) as compared to wildtype 
mice.  Equally important, oral dose escalation studies revealed that AUC and Cmax 
profiles in huPepT1 mice over a large dose range exhibited non-linear 
pharmacokinetics, as seen in human clinical trials (Weller et. al, 1993), but unlike the 
linear pharmacokinetics observed in wildtype mice (Posada and Smith, 2013).  The 
huPepT1 mouse line, therefore, demonstrated its use as a potential model for predicting 
human pharmacokinetics involving compounds that are mainly absorbed by the action 
of PepT1.  Nonetheless, huPepT1 mice have not been tested with respect to their in situ 
intestinal permeability, and in vivo absorption and disposition kinetics of prodrugs. 
 With this in mind, the purpose of the current study was to evaluate the intestinal 
permeability, oral absorption and disposition of the ester prodrug valacyclovir in a 
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huPepT1 transgenic mouse model.  We hypothesized that valacyclovir would exhibit a 
higher affinity for intestinal transport in huPepT1 mice, and that the rate of absorption 
and extent of systemic exposure would be lower than that observed in wildtype mice.  In 
particular, initial studies evaluated the in situ intestinal permeability and kinetics of the 
transport of valacyclovir, the specificity of prodrug transport, and the intestinal segment-
dependent permeability of valacyclovir in both wildtype and huPepT1 mice.  Subsequent 
studies evaluated the in vivo oral and intravenous pharmacokinetics of valacyclovir (and 
acyclovir) as related to oral absorption, systemic exposure, and bioavailability. 
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3.3 Materials and Methods 
 
3.3.1 Chemicals 
  
 
 Valacyclovir, acyclovir,  glycylsarcosine (Gly-Sar), cephalexin, tetraethylammonium 
(TEA),  L-histidine, L-lactate and L-valine were purchased from Sigma-Aldrich (St. 
Louis, MO). CytoScintTM scintillation solution were purchased from MP Biomedicals 
(Solon, OH). [3H]Valacyclovir (1.1 Ci/mmol) and [3H]acyclovir (10.6 Ci/mmol) were 
purchased from Moravek Biochemicals and Radiochemicals (Brea, CA).  [14C]Inulin 
5000 (1.1 mCi/g) was purchased from American Radiolabeled Chemicals (St. Louis, 
MO).   
 
3.3.2 Animals 
  
 
 Gender-matched and age-matched (8-12 weeks) mice utilized in these studies have 
a C57BL/6 background and consisted of the mPepT1+/+ (wildtype) and mPepT1-/-
/huPepT1+/- (humanized PepT1) genotypes.  The viability and functional activity of the 
humanized PepT1 mouse line were previously established in our laboratory (Hu et. al 
2014).  Inheritance of the huPepT1 gene was confirmed by genotyping. All mice were 
bred and housed in a temperature-controlled environment with 12 hour light and dark 
cycles, and a standard diet and water ad libitum (Unit for Laboratory Animal Medicine, 
University of Michigan, Ann Arbor, MI). Animal studies were conducted in accordance 
with the Guide for the Care and Use of Laboratory Animals.   
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3.3.3 In Situ Single-Pass Intestinal Perfusion Studies 
 
 As reported previously (Yang and Smith, 2013; Jappar et. al, 2010), wildtype and 
huPepT1 mice were fasted overnight (14-18 hours) before experimentation.  Mice were 
then given 40-60 mg/kg of pentobarbital as an intraperitoneal injection for anesthesia.  
The abdominal area was sanitized with alcohol before a 1.5 cm incision was made 
along the midline section.   An 8-cm segment of jejunum (~2 cm distal to the Ligament 
of Trietz) was then isolated, cannulated (2.0 mm outer diameter), and tied off with silk 
sutures.  The mouse was then placed in a temperature-controlled chamber (31°C) and 
saline-wetted gauze, along with Parafilm, was laid out across the abdominal section to 
prevent dehydration.    A syringe containing pH 6.5 perfusion buffer (10 mM MES/Tris, 
135 mM NaCl, 5 mM KCl), and 50 μM valacyclovir, was housed in a syringe pump 
(Harvard Apparatus PHD Ultra, South Natick, MA).  Inlet tubing connected the syringe 
to the perfused segment and outlet tubing connected the perfused segment to the 
collection vials. Buffer solution was perfused through the cannulated segment at a 
programmed flow rate of 0.1 mL/min for 90 minutes.  Perfusate samples were collected 
every 10 minutes for the last 60 minutes of the perfusion.  No samples were collected 
during the first 30 minutes in order to pass over the pre-equilibration period. Upon 
completion, the perfused intestinal segments were removed, and the length was 
measured and recorded.  
 Concentration-dependent studies were conducted by perfusing valacyclovir through 
the jejunum at concentrations ranging from 0.05-30 mM in wildtype mice and from 
0.025-1 mM in huPEPT1 mice. Additionally, inhibition studies conducted in both 
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genotypes evaluated the specificity of valacyclovir transport from the jejunum.  
Valacyclovir was perfused at 50 μM either alone (control) or with inhibitors at 25 mM.  
Potential inhibitors included glycylsarcosine (Gly-Sar), cephalexin, tetraethylammonium 
(TEA), L-histidine, L-lactate, and L-valine.  All perfusion buffers containing inhibitors had 
their pH readjusted to 6.5, as needed.  
 For segment-dependent studies, 50 μM valacyclovir was simultaneously perfused 
through a 2 cm segment of duodenum (~0.25 cm distal to the pyloric sphincter), the 
jejunum (as described before), a 6 cm segment of the ileum (~1 cm proximal to the 
cecum), and a 3 cm segment of the colon (~0.5 cm distal to the cecum). 
 
3.3.4 UPLC Analytical Method  
 
 All perfusate samples were analyzed by a UPLC Waters Acquity H-class system.  
Peaks corresponding to valacyclovir and acyclovir were separated by a gradient method 
through a 100-cm Acquity HSS T3 column.  The method starts with 100% water in 0.1% 
TFA, and changes linearly over the next five minutes to 90% water/10% acetonitrile.  
This ratio holds for 2 minutes before reverting back to 100% aqueous content almost 
instantly. Each sample run lasts 12 minutes to ensure column pressure equilibration. 
Column temperature was maintained at 40°C and the flow rate remained constant at 0.5 
mL/min. Compounds were detected by UV detection at 254 nm and retention times 
were approximately 2.4 and 4.9 minutes for acyclovir and valacyclovir, respectively.  All 
perfusate samples were centrifuged at 15000 rpm for 10 minutes and 25 L aliquots of 
supernatant were injected into the column by automation. 
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 Method validation over three consecutive days showed accuracy within 6% of 
specified values and precision within 2% (relative standard deviation). Linearity was 
established from 0.5-50 M for acyclovir and from 2-200 M for valacyclovir. The limits 
of quantitation for acyclovir and valacyclovir in perfusion buffer were 50 and 10 nM 
respectively.  Additionally, the examination of blank perfusate samples showed that 
endogenous compound noise was essentially absent within the analyte retention time 
windows. 
 
3.3.5 Intravenous and Oral Administration Studies 
 
 IV bolus and oral administration studies were conducted in a similar manner to that 
reported previously (Sugawara et. al, 2000).  For IV bolus studies mice were 
administered, by tail vein, 100 μL of saline solution containing 24 nmol/g of acyclovir 
and [3H] acyclovir (5 μCi/mouse).  Blood samples (~20 μL) were collected by tail nick at 
1, 5, 10, 20, 30, 45, 60, 90, 120 and 180 minutes after administration.  Prior to the oral 
studies, mice were fasted overnight (16-18 hours) before being administered 200 μL of 
saline solution containing 24 nmol/g of valacyclovir and [3H] valacyclovir (10 μCi/mouse) 
by oral gavage. Blood samples were collected similarly as described for IV bolus, with 
the exception that the first collection time was at 2 minutes. Blood samples from both 
studies were placed in microcentrifuge tubes with K3-EDTA and centrifuged for 3 
minutes at 3000 rpm.  Aliquots (5 μL) of plasma were placed in scintillation vials along 
with 6 mL of CytoScint scintillation fluid (MP Biomedicals, Solon, OH).  The plasma 
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samples were placed in a dual-channel liquid scintillation counter (Beckman LS 6000 
SC, Beckman Coulter Inc., Brea, CA) and radioactivity was measured. 
 
3.3.6 Mass Balance Studies 
 
 Mice were fasted overnight (16-18 hours) and then 100 μL [14C]inulin (5 μCi/mouse) 
was injected by IV bolus in the tail vein.  Immediately after, these mice were 
administered 24 nmol/g valacyclovir with [3H]valacyclovir (10 μCi/mouse) by oral 
gavage.  Mice were then placed in a metabolic cage for 24 hours for the purpose of 
separately collecting the urine and feces.  Food and water were provided to the mice 
while in the cage.  After several cage washes, 5-10 μL aliquots of the diluted urine and 
feces were placed in separate vials with 6 mL of scintillation fluid, and radioactivity was 
measured by the scintillation counter. 
 
3.3.7 Data Analysis  
 
 For in situ perfusion studies, the calculation of effective permeability (Peff) assumed 
a complete radial mixing (parallel tube) model (Komiya et. al, 1980; Kou et. al, 1991): 
 
𝑃𝑒𝑓𝑓 =  
−𝑄𝑖𝑛 ×  ln (
𝐶′𝑜𝑢𝑡
𝐶𝑖𝑛 )
2𝜋𝑅𝐿
 
(1) 
where Qin is the inlet perfusion flow rate (0.1 mL/min), C’out is the sum of valacyclovir 
and acyclovir concentrations in the outlet perfusate corrected for water flux, Cin is the 
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concentration of valacyclovir in the inlet perfusate, R is the intestinal radius (0.1 cm for 
small intestine and 0.2 cm for colon), and L is the intestinal segment length.  The 
equation used to determine C’out was calculated as: 
𝐶′𝑜𝑢𝑡 = (𝐶𝑜𝑢𝑡, 𝑉𝐴𝐶𝑉 + 𝐶𝑜𝑢𝑡, 𝐴𝐶𝑉 − 𝐶𝑖𝑛, 𝐴𝐶𝑉)  × (
𝑄𝑜𝑢𝑡
𝑄𝑖𝑛
) 
(2) 
where Qout is determined gravimetrically (Sutton et. al, 2001).  Concentration-dependent 
studies in both wildtype and huPepT1 mice were modeled according to Michaelis-
Menten kinetics: 
𝑉 = 𝑃𝑒𝑓𝑓 ×  𝐶𝑖𝑛 =
𝑉𝑚𝑎𝑥 ×  𝐶𝑖𝑛
𝐾𝑚 + 𝐶𝑖𝑛
  
(3) 
where Vmax is the maximal velocity of transport and Km is the transporter affinity in terms 
of the inlet concentration of valacyclovir.  The kinetic data was modeled by nonlinear 
regression and assessed for goodness of fit using Prism version 7 software (GraphPad 
Software, Inc., La Jolla, CA). 
 Data were reported as mean ± SD, unless noted differently.  Comparisons 
between two groups were assessed by the unpaired t–test.  Comparisons between 
multiple groups were analyzed by one-way ANOVA followed by either Dunnett’s or 
Tukey’s test using Prism software.  Statistical significance was attributed when p  0.05.  
For oral and IV bolus studies, pharmacokinetic parameters were determined by 
noncompartmental analysis using Phoenix WinNonlin 8.0 software (Certara, St Louis). 
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3.4 Results 
 
 
3.4.1 Valacyclovir Transport Kinetics During In Situ Jejunal Perfusions  
 
 
 Both wildtype and huPepT1 mice exhibited distinctive Michaelis-Menten kinetics for 
valacyclovir uptake with characteristic transport saturability (Figures 3.1, 3.2 and 3.3).  
The kinetic parameters for wildtype mice (Figure 3.1) were Vmax = 782 ± 53 
pmol/cm2/sec and Km = 7.7 ± 1.0 mM (r2=0.992), and for huPepT1 mice (Figure 3.2) 
were Vmax = 7.83 ± 1.37 pmol/cm2/sec and Km = 0.25 ± 0.10 mM (r2=0.898).  The Vmax 
value was approximately 100-fold greater in wildtype mice than in huPepT1 mice, while 
the Km value was approximately 30-fold less (i.e. affinity was 30-fold greater).  The 
inclusion of a nonsaturable term did not improve the goodness of fit, so only a saturable 
term was considered in the final model.   
 
3.4.2 mPepT1 and huPepT1 Specificity for Valacyclovir Transport During In Situ Jejunal 
Perfusions 
 
 The co-perfusion of various potential inhibitors with valacyclovir in wildtype mice 
(Figure 3.4) demonstrated that glycylsarcosine and cephalexin significantly reduced the 
permeability of valacyclovir by approximately 2-fold from the control value.  In contrast, 
the substrates tetraethylammonium, L-histidine, L-lactate, and L-valine did not 
significantly change valacyclovir permeability.  These same inhibitor studies in huPepT1 
mice (Figure 3.5) showed a significant 16-fold reduction in the permeability of 
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valacyclovir by glycylsarcosine, whereas cephalexin did not induce a significant 
reduction. Moreover, co-perfusion of valacyclovir with other potential inhibitors did not 
significantly change the permeability from control values, as similarly observed in the 
wildtype results. 
 
3.4.3 Regional Valacyclovir Permeability During In Situ Intestinal Perfusions 
 
 The permeability of valacyclovir, obtained from segments of the small intestine, 
were shown to be significantly different between, but not within, the two genotypes 
(Figure 3.6).  The huPepT1 mice had permeability values that were substantially smaller 
than wildtype mice and were approximately 12-fold lower in the duodenum, 10-fold 
lower in the jejunum, and 7-fold lower in the ileum.  On the other hand, permeability 
values from the colon were not different between wildtype and huPepT1 mice and, in 
huPepT1 animals, were not different from other segments of the small intestine.  
 
3.4.4 Pharmacokinetic Parameters In Vivo from IV Bolus and Oral Administrations  
 
 The IV bolus administration of acyclovir in wildtype and huPepT1 mice yielded 
pharmacokinetic profiles that were nearly superimposable between the two genotypes 
(Figure 3.7).  This observation is supported by the pharmacokinetic analysis in which all 
key parameters showed no significant differences between the wildtype and huPepT1 
mice (Table 3.1).  In contrast, the oral administration of valacyclovir produced plasma 
concentration-time curves of acyclovir that were visually different between the two 
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genotypes (Figure 3.8).  This difference was noted by the 3-fold higher Cmax in wildtype 
mice, the 3-fold larger Tmax in huPepT1 mice, and the AUC0-180 of huPepT1 mice that 
was approximately 80% of the value seen in wildtype animals (Table 3.2).  Despite 
these trends, only the Cmax values were statistically different from each other. 
 
3.4.5 Acyclovir Bioavailability In Vivo from Mass Balance Studies  
 
 As shown in Table 3.3, the bioavailability of acyclovir, after oral administration of 
valacyclovir, was 77.5% and 52.8% for wildtype and huPepT1 mice, respectively.  This 
significant difference corresponds to a relative bioavailability in huPept1 mice that was 
68% of the value seen in wildtype animals.  Although the urine from huPepT1 mice 
contained 20% less of the administered dose, their feces contained approximately 20% 
more of the dose, as compared to wildtype mice.  Inulin, a marker for urine collection 
efficiency, revealed adequate recoveries of drug-related radiolabel in these studies 
(~90%).  Additionally, trace amounts of inulin in the feces (~1%) confirmed that there 
was a minimal level of urine-to-feces cross-contamination. 
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3.5 Discussion 
 
 Applicability of the huPepT1 transgenic mouse line for predicting clinical 
pharmacokinetic parameters has been validated recently through studies performed 
with cefadroxil (Hu and Smith, 2016). However, these findings were limited in scope 
because the substrates that PepT1 can transport encompass more than just β-lactam 
antibiotics (Rubio-Aliaga and Daniel, 2002; Dahan et. al, 2014; Brandsch et. al, 2013).  
The current study has sought to broaden the utility of these transgenic mice by further 
validating the model with the ester prodrug valacyclovir.  Specifically, several major 
findings were revealed: 1) huPepT1 mice had a greater affinity (30-fold lower Km) and 
reduced capacity (100-fold lower Vmax) for valacyclovir during jejunal perfusions than 
wildtype mice; 2) the jejunal permeability of valacyclovir was specific for PepT1; 3) the 
permeability of valacyclovir was significantly lower in all segments of huPepT1 mouse 
small intestine as compared to wildtype; 4) the disposition kinetics of intravenously 
administered valacyclovir did not differ between the two genotypes; and 5) the relative 
bioavailability of orally dosed valacyclovir was about 30% lower in huPepT1 mice than 
wildtype animals, and its absolute bioavailability in huPepT1 mice was better correlated 
with clinical studies.  
 In a previous perfusion study, Yang and Smith (2013) reported the jejunal transport 
kinetics of valacyclovir as Vmax = 1.4 nmol/cm2/s and Km = 10.2 mM in wildtype mice.  
These values were comparable to those obtained in the current study (i.e., Vmax = 0.78 
nmol/cm2/s and Km = 7.71 mM).  In regard to hPepT1-mediated transport, previous cell 
culture studies revealed Km values ranging from 0.29 - 5.94 mM (Balimane et. al, 1998; 
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Han et al, 1998; Guo et. al, 1999; Balimane and Sinko, 2000; Bhardwaj et. al, 2005).  In 
the current study, huPepT1 mice had a Km of 0.25 mM, a value approaching the lower 
bounds of the literature range.  The reasons for variation between our in situ perfusion 
studies and other in vitro studies may be attributed to the use of different cell expression 
systems, a lack of blood flow during in vitro studies, and differences in buffer pH that 
may alter valacyclovir affinity for PepT1 (Balimane and Sinko, 2000).   
 An understanding of PepT1 specificity for valacyclovir in the huPepT1 mouse model 
is paramount for model validation.  Inhibition studies, conducted in both wildtype and 
huPepT1 mice, indicated that L-valine, L-histidine, L-lactate and tetraethylammonium 
had little to no effect on valacyclovir-mediated uptake, thereby, ruling out an influence of 
ATB0,+, PhT1/2, MCT1 and OCT transporters.  Conversely, the reduction in valacyclovir 
uptake during co-perfusion of glycylsarcosine and cephalexin indicated that valacyclovir 
was transported substantially by PepT1 in both mouse models.  This finding is in 
agreement with a similar study in wildtype mice by Yang and Smith (2013), with the 
novelty of also testing MCT1 given its known expression in mouse small intestine 
(Iwanaga et. al, 2006).  It is noteworthy to mention that cephalexin did not significantly 
reduce valacyclovir uptake in huPepT1 mice, although a trend was observed.  This may 
have to do with differences in inhibitor affinity of cephalexin for this transporter.  Two 
previous studies in Caco-2 cells (pH 6.0 uptake buffer) revealed that the Km values for 
glycylsarcosine and cephalexin were approximately 4-fold different (i.e., 2 and 8 mM 
respectively) (Irie et. al, 2005; Watanabe et. al, 2006).   
 With respect to segment-dependency, wildtype mice showed uptake trends that 
were roughly similar to the relative levels of protein expressed in each segment (Jappar 
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et. al, 2010).  However, segment-dependent uptake in huPepT1 mice did not 
correspond well with protein levels.  While uptake was low and statistically similar 
across all segments, our previous study reported higher protein levels in the small 
intestine and only trace amounts in the colon (Hu and Smith, 2016).  This “apparent” 
discrepancy is hard to reconcile.  However, a similar study with cefadroxil revealed non-
significant differences in uptake between the small and large intestines of huPepT1 
mice, although greater differences were observed (Hu and Smith, 2016). 
 In a clinical study, where 10 M of valacyclovir was perfused through the subject’s 
jejunum using the Loc-I-Gut® method (pH 6.5 sodium phosphate buffer), the effective 
permeability was reported as 1.66 x 10-4 cm/s (Cao et. al, 2006). In the current study, 
the jejunal permeability of 50 M valacyclovir was 0.92 x 10-4 in wildtype mice and 0.12 
x 10-4 cm/s in huPepT1 mice.  Using these permeability values, it was possible to 
estimate the absorption rate constant (Ka) of valacyclovir by the equation: 
𝐾𝑎 = (2 ×  𝑃𝑒𝑓𝑓)/𝑅 
(4) 
where R is the intestinal radius of the jejunum (1.75 cm for humans and 0.1 cm for 
mice) (Yu et. al, 1999).  Accordingly, the Ka values were 0.68 hr-1 in humans, 6.62 hr-1 in 
wildtype and 0.86 hr-1 in huPepT1 mice (Table 3.4), indicating a better correlation in the 
absorption rate constant between humans and huPepT1 mice. Thus, it appears that 
huPepT1 transgenic mice may predict the absorption of valacyclovir in humans with 
improved accuracy.  
 The 24 nmol/g valacyclovir dose chosen for all in vivo experiments in the current 
study was selected from the 10-100 nmol/g dosing range established previously (Yang 
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et. al, 2013).  These authors justified the dosing range by relating the Cmax values of 
acyclovir obtained from their wildtype mice with the Cmax values determined from clinical 
studies in which 250, 500, 1000 and 2000 mg oral doses of valacyclovir were 
administered (Weller et. al, 1993). Apart from establishing dosing rationale, 
pharmacokinetic trends can be elucidated from these studies as well. For example, 
escalating oral doses of valacyclovir in wildtype mice revealed linear increases in 
acyclovir AUC and Cmax, but clinical studies showed less than proportional increases in 
these parameters.  Investigators (Yang et. al, 2013; Weller et. al, 1993) have attributed 
these clinical trends to saturation of transporter-mediated intestinal absorption, which 
we believe is substantiated by comparing the oral absorption results in the current study 
between wildtype and huPepT1 mice. 
 The in vivo oral absorption and disposition of 25 nmol/g valacyclovir has been 
reported previously in wildtype and PepT1 knockout mice (Yang et. al, 2013). In these 
studies, PepT1 knockout mice had a lower Cmax (5- to 6-fold), a higher Tmax (5-fold), and 
an AUC0-180 for acyclovir that was 35% of that observed in wildtype mice. While PepT1 
ablation clearly demonstrated a deep reduction in the rate and extent of oral valacyclovir 
absorption, more modest differences were observed between wildtype and huPepT1 
mice (Table 3.2).  Nonetheless, as clearly shown by our mass balance studies (Table 
3.3), the bioavailability of orally administered valacyclovir was 52.8% in huPepT1 mice, 
as compared to 77.5% for wildtype animals.  Notably, a similar bioavailability was 
observed in the clinical setting where a value of 51.3% was observed after the oral 
administration of 1000 mg valacyclovir (Soul-Lawton et. al, 1995).  It is worth mentioning 
that the bioavailability of acyclovir as determined from the AUC0-180 values, derived from 
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the oral and IV bolus studies (Tables 3.2 and 3.3), were 106% and 76.4% for wildtype 
and huPepT1 mice, respectively.  While a similar reduction in bioavailability is evident in 
huPepT1 mice, the results from the mass balance studies are believed to be superior 
for the following reasons: 1) only a single population of mice is needed to determine 
bioavailability in these mass balance studies and 2) only partial AUC values are utilized 
in the IV bolus and oral administration studies. 
 As shown previously by our group, jejunal permeabilities that differed by 10-fold 
between wildtype and PepT1 knockout mice resulted in systemic availabilities that 
differed by only 2-fold for glycylsarcosine (Jappar et. al, 2010; Jappar et. al, 2011) and 
by 2- to 3-fold for valacyclovir (Yang and Smith, 2013; Yang et. al, 2013) after oral 
dosing.  In these reports, we advanced the concept that PepT1 knockout mice may take 
advantage of the residual length of small and large intestines, resulting in greater than 
expected passive absorption and, thereby, minimizing the reduced systemic availability 
of substrate expected during PepT1 ablation.  This concept was subsequently validated 
during an in silico analysis by our group (Yang and Smith, 2017), demonstrating that 
whereas wildtype mice primarily absorb valacyclovir in the duodenal and jejunal 
segments of the small intestine (i.e., 66% of a total 70% absorbed), the absorption of 
valacyclovir in PepT1 knockout mice was slow but sustained throughout the entire 
intestinal tract (i.e. 4% duodenum, 14% jejunum, 10% ileum and 12% cecum/colon for a 
total 40% absorbed).  Although a similar analysis was not performed for valacyclovir in 
huPepT1 mice, this transgenic group appears to fall in the middle of the results 
observed between wildtype and PepT1 knockout mice, namely, having an absorption of 
53%. 
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 An underlying assumption throughout these studies was that valacyclovir was 
rapidly degraded to its parent compound in vivo and that the radiolabel being measured 
was essentially all acyclovir.  We believe, for several reasons, that this was a 
reasonable assumption.  First, Yang and Smith (2013) found that after a 90-min 
intestinal perfusion of valacyclovir, only acyclovir was observed in the portal venous 
blood of mice.  Second, these investigators reported very similar plasma concentration-
time profiles of acyclovir in mice following oral administration of either radiolabeled or 
unlabeled valacyclovir, as measured by liquid scintillation counting or HPLC, 
respectively.  Finally, studies in humans, monkeys and rats also confirmed the rapid and  
efficient metabolic conversion of prodrug (Weller et. al, 1993; Burnette and de Miranda, 
1994; de Miranda and Burnette, 1994). 
 In conclusion, the in situ mechanistic studies provided here demonstrate that 
valacyclovir has a greater affinity (and lower capacity) for PepT1-medidated transport in 
huPepT1 than wildtype mice.  The in vivo pharmacokinetic and mass balance studies 
reflect the saturability of intestinal uptake in huPepT1 mice, as judged by decreases in 
valacyclovir’s rate and extent of absorption or bioavailability.  Taken as a whole, the 
discrete differences in wildtype and huPepT1 mice, when held against clinical data, 
further rationalize the usefulness of this transgenic model for studying other prodrugs.  
The huPepT1 mice, along with other transgenic mouse models, are currently being 
used to evaluate the feasibility of developing oral prodrugs for parenteral anti-cancer 
therapeutics. 
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3.7 Figures and Tables 
 
 
 
 
 
Figure 3.1 Uptake of valacyclovir after in situ perfusion of wildtype mice at given 
perfusate concentrations.  Data are expressed as mean±S.E. (n=3-4).  Mean data was 
fit into the model.  Inset shows the data points at low valacyclovir concentrations. 
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Figure 3.2 Uptake of valacyclovir after in situ perfusion of huPepT1 mice at given 
perfusate concentrations.  Data are expressed as mean±S.E. (n=3-7).  Mean data was 
fit into the model.  Inset shows the data points at low valacyclovir concentrations. 
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Figure 3.3 Comparison of in situ perfusions of valacyclovir in wildtype and huPepT1 
mice.  All data are expressed as mean±S.E. (n=3-7). Mean data was fit into model.   
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Figure 3.4 Valacyclovir at 50 µM was co-perfused (pH 6.5) with various potential 
inhibitors at 25 mM in wildtype mice (n=3-7).  The control column represents the 
perfusion of valacyclovir alone.  *p  0.05 compared to control, as determined by 
ANOVA and Dunnett’s’ test.  
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Figure 3.5 Valacyclovir at 50 µM was co-perfused (pH 6.5) with various potential 
inhibitors at 25 mM in huPepT1 mice (n=5-8).  The control column represents the 
perfusion of valacyclovir alone.  *p  0.05 compared to control, as determined by 
ANOVA and Dunnett’s’ test.  
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Figure 3.6 All four intestinal segments were perfused simultaneously with valacyclovir 
in both wildtype and huPepT1 mice.  Data are expressed as mean ± SE (n=4).  
Segments with the same letter were not significantly different, as determined by ANOVA 
and Tukey’s test.  
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Figure 3.7 Acyclovir plasma concentration-time profile after IV bolus administration of  
24 nmol/g of acyclovir in wildtype and huPept1 mice.  Data are expressed as mean ±  
SE (n=4).  
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Figure 3.8 Acyclovir plasma concentration-time profiles after oral administration of 24 
nmol/g of valacyclovir in wildtype and huPept1 mice. Data are expressed as mean ± SE 
(n=4). 
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Table 3.1 Pharmacokinetic parameters of acyclovir after IV bolus administration of 
acyclovir (24 nmol/g) in wildtype and huPeptT1 mice  
 
 
Data are shown as mean  SD (n=4).  No significant difference was observed for any of 
the key parameters, as determined by unpaired t-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter (unit) Wildtype huPepT1 Ratio (huPepT1/WT) 
Vdss (L/kg) 2.1 ± 0.8 1.4 ± 0.2 0.67 
CL (L/hr/kg) 1.3 ± 0.2 1.3 ± 0.2 1.0 
T0.5 (min) 106 ± 46 63.4 ± 4.0 0.60 
AUC0-180 min (M*min) 929 ± 126 1015 ± 92 1.1 
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Table 3.2 Pharmacokinetic parameters of acyclovir after oral administration  
of valacyclovir (24 nmol/g) in wildtype and huPept1 mice  
 
 
Data are shown as mean  SD (n=4). *p  0.05 compared to wildtype mice, as 
determined by unpaired t-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter (unit) Wildtype huPepT1 Ratio (huPepT1/WT) 
Tmax (min) 10 ± 0 33 ± 19 3.3 
Cmax (M) 18.0 ± 6.5 6.1 ± 1.4* 0.34 
AUC0-180 min (M*min) 982 ± 230 775 ± 86 0.79 
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Table 3.3 Bioavailability of acyclovir after the oral administration of valacyclovir (24 
nmol/g) in wildtype and huPepT1 as determined from mass balance  
 
 
Data are expressed as mean values and represent three mice per group. Each animal 
was injected with [14C]inulin (Inu) by IV bolus, and then dosed with [3H]valacyclovir 
[VACV] by oral gavage. Animals were then placed in a metabolic cage, and the urine 
and feces collected over 24 hours.  Bioavailability (F) of acyclovir (ACV) was calculated 
as: %ACV recovered in the urine divided by %Inu recovered in the urine.  Bioavailability 
(F) of Inu was calculated as: %Inu recovered in the urine plus %Inu recovered in the 
feces. *p  0.05 compared to wildtype mice, as determined by unpaired t-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Wildtype  huPepT1 
 Urine Feces F  Urine Feces F 
% Acv 68.1 11.6 77.5  47.4 31.6 52.8* 
% Inu 87.9 1.4 89.3  89.1 0.5 89.6 
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Table 3.4 The effective permeability and calculated Ka of the prodrug valacyclovir as 
determined from the jejunum in humans, wildtype and huPepT1  
transgenic mice 
 
 
 
Model 
 
Peff (cm/s) x 10-4 Ka (hr-1) 
Clinical 1.66* 
 
0.68 
HuPepT1 0.12 
 
0.86 
Wildtype 0.92 
 
6.62 
 
 
* Value taken from Cao et. al., 2006. 
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CHAPTER 4 
 
The Effect of Nifedipine on the Intestinal Permeability of  
 
Valacyclovir in Wildtype Mice 
 
 
 
4.1 Abstract  
 
 
 There have been many drug interaction studies conducted in the past that have  
 
investigated the influence of the calcium channel blocker nifedip ine on the  
 
absorption and pharmacokinetics of various PepT1 substrates belonging to a  
 
single class of β-lactam antibiotics.  The results from the clinical and rat  
 
administration studies found that nifedipine significantly enhanced the absorption  
 
of these compounds.  Therefore, the focus of the current investigation was to  
 
ascertain if the absorption-enhancing effects of nifedipine could be extended to  
 
other PepT1 substrates, specifically to the prodrug valacyclovir.  Wildtype mice  
 
were co-perfused with valacyclovir and nifedipine and the results revealed that  
 
the intestinal permeability of the prodrug was non-statistically diminished (i.e. 26- 
 
28%) in the presence of this calcium channel blocker. While the outcomes from  
 
these experiments have been difficult to reconcile in light of previous studies,  
 
perhaps the valacyclovir-nifedipine interaction involves a species-dependent  
 
mechanism that denies absorption-enhancing effects in mice. 
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4.2 Introduction 
 
 
 Drug-drug interactions have become an emerging concern for government  
 
regulators and drug developers alike over the last couple decades, with guidance  
 
for the industry first established in 1997.  This concern was so evident that from  
 
1999-2003 half of all drugs pulled from US markets were due to undesirable  
 
drug interactions.  These interactions occur when a “perpetrator” compound  
 
affects the pharmacokinetic profile of a “victim” compound by altering its  
 
absorption, distribution, metabolism, or excretion.   At first, much effort was  
 
placed on trying to understand interactions that were mediated by changes in  
 
metabolic activity, particularly with cytochrome P450 enzymes.  However, this  
 
field has expanded recently with drug transporters now considered important  
 
mediators in drug interactions as well (Prueksaritanont et. al, 2013; Huang et. al,  
 
2013). 
 
 There are many drug-drug interaction studies from the literature that  
 
suggest the calcium channel blocker nifedipine can enhance the oral absorption  
 
of β-lactam antibiotics, a class of drugs absorbed by the action of PepT1 (Rubio- 
 
Aliaga and Daniel, 2002).  Specifically, two clinical interaction studies with amoxicillin  
 
and cefixime (Westphal et. al, 1990; Duverne et. al, 1992), and one oral administration  
 
study with cephalexin in rats (Berlioz et. al, 2000) have supported this premise.   
 
Furthermore, nifedipine was found to enhance the intestinal absorption of  
 
cephalexin and cefixime after a series of intestinal perfusions conducted in rats  
 
(Harcouet et. al, 1997; Berlioz et. al, 1999). Interestingly, the same trend was  
 
88 
 
observed for cefixime in Caco-2 cells (Wenzel et. al, 2002), where the authors  
 
attributed an increase in uptake to a concomitant increase in PepT1-mediated  
 
activity (due to an elevated proton gradient). 
  
Despite the insight provided from these previous drug interaction studies,  
 
it remains to be seen if other PepT1 substrates that are not β-lactam antibiotics  
 
will act similarly in the presence of nifedipine.  Thus, the purpose of this current study is  
 
to examine and assess the potential interaction between the prodrug valacyclovir (a  
 
PepT1 substrate) and nifedipine in wildtype mice.  The underlying hypothesis is that the  
 
co-administration of nifedipine will enhance the intestinal absorption of valacyclovir.   
 
Therefore, intestinal perfusions in wildtype mice have been carried out to determine the  
 
impact of nifedipine on the permeability of this prodrug.    
 
 
 
 
 
 
 
 
 
 
 
 
 
89 
 
4.3 Materials and Methods 
 
3.3.1 Chemicals 
  
 
 Valacyclovir and nifedipine were purchased from Sigma-Aldrich (St. Louis, MO). 
CytoScintTM scintillation solution was purchased from MP Biomedicals (Solon, OH). 
[3H]Valacyclovir (1.1 Ci/mmol) was purchased from Moravek Biochemicals and 
Radiochemicals (Brea, CA).  [14C]Inulin 5000 (1.1 mCi/g) was purchased from American 
Radiolabeled Chemicals (St. Louis, MO).  All other buffer components were purchased 
from standard sources. 
 
3.3.2 Animals 
  
 
 Gender-matched and age-matched (8-12 weeks) wildtype mice are utilized in these 
studies and have a C57BL/6 background.  All mice were bred and housed in a 
temperature-controlled environment with 12 hour light and dark cycles, and a standard 
diet and water ad libitum (Unit for Laboratory Animal Medicine, University of Michigan, 
Ann Arbor, MI). Animal studies were conducted in accordance with the Guide for the 
Care and Use of Laboratory Animals.   
 
3.3.3 Perfusate Buffer Composition 
  
 
 The buffer solution used in the following intestinal perfusion studies was  
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partially adopted from the drug interaction studies conducted by Wenzel et. al  
 
(2002). It is a modified Krebs buffer with 10 mM HEPES, 0.3 mM KH2PO4, 0.3  
 
mM NaH2PO4, 1.0 mM MgSO4, 2.8 mM CaCl2, 5.4 mM KCl, 137 mM NaCl, and  
 
10 mM β-D-glucose.  Tris was added to the solution to achieve pH 6.5.  The non- 
 
absorbable marker [14C]inulin 5000 (0.18 μCi/mouse) was added to solution to  
 
account for changes in water flux, as done before (Hu and Smith, 2016).  Valacyclovir  
 
was perfused at 50 μM with [3H]valacyclovir (1.8 μCi/mouse), while 90-100 μM  
 
nifedipine was added during co-perfusions.  
 
 
3.3.4 In Situ Single-Pass Intestinal Perfusion Studies 
 
 
 
 As reported previously (Yang and Smith, 2013; Jappar et. al, 2010), wildtype mice 
were fasted overnight (16-18 hours) before experimentation.  Mice were then given 40-
60 mg/kg of pentobarbital as an intraperitoneal injection for anesthesia.  The abdominal 
area was sanitized with alcohol before a 1.5 cm incision was made along the midline 
section.   An 8-cm segment of jejunum (~2 cm distal to the Ligament of Trietz) was  
isolated, cannulated (2.0 mm outer diameter), and tied off with silk sutures.  The mouse 
was then placed in a temperature-controlled chamber (31°C) and saline-wetted gauze, 
along with Parafilm, was laid out across the abdominal section to prevent dehydration.  
Inlet tubing connected the syringe (which contained the perfusion buffer) to the intestinal 
segment and outlet tubing connected the intestinal segment to the collection vials.  
 Buffer solution was perfused through the cannulated segment at a programmed 
flow rate of 0.1 mL/min for 90 minutes by the action of a Harvard Apparatus PHD 
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syringe pump (South Natick, MA). Two different perfusion schedules were utilized in 
these studies. In the first study, valacyclovir and nifedipine were co-perfused for the first 
10 minutes while valacyclovir was perfused alone for the remaining 80 minutes.  In the 
second study, valacyclovir and nifedipine were co-perfused for the first 30 minutes while 
valacyclovir was perfused alone for the remaining 60 minutes.  Perfusate samples were 
collected every 10 minutes for the last 60 minutes for each schedule.  Upon completion, 
the perfused intestinal segments were removed, and the length was measured and 
recorded.  Aliquots (100 μL) of inlet and outlet perfusate were placed in scintillation vials 
along with 6 mL of CytoScint scintillation fluid (MP Biomedicals, Solon, OH).  These 
samples were placed in a dual-channel liquid scintillation counter (Beckman LS 6000 
SC, Beckman Coulter Inc., Brea, CA) and radioactivity was measured. 
 
3.3.5 Data Analysis  
 
 For in situ perfusion studies, the calculation of effective permeability (Peff) assumed 
a complete radial mixing (parallel tube) model (Komiya et. al, 1980; Kou et. al, 1991): 
 
 
𝑃𝑒𝑓𝑓 =  
−𝑄𝑖𝑛 ×  ln (
𝐶′𝑜𝑢𝑡
𝐶𝑖𝑛 )
2𝜋𝑅𝐿
 
(1) 
where Qin is the inlet perfusion flow rate (0.1 mL/min), C’out is the sum of valacyclovir 
and acyclovir concentrations in the outlet perfusate corrected for water flux, Cin is the 
concentration of valacyclovir in the inlet perfusate, R is the intestinal radius (0.1 cm for 
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small intestine and 0.2 cm for colon), and L is the intestinal segment length.  The 
equation used to determine C’out was calculated as: 
𝐶′𝑜𝑢𝑡 = 𝐶𝑜𝑢𝑡 × (𝐼𝑁𝑈𝑖𝑛/𝐼𝑁𝑈𝑜𝑢𝑡) 
(2) 
where INUin and INUout are the inlet and outlet counts of [14C]Inulin 5000 contained 
within the perfusate (Sutton et. al, 2001).  
 Data were graphed on Prism software (Irvine, CA) and reported as mean ± SE.  
Comparisons between two groups were assessed by the unpaired t–test.   
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4.4 Results 
 
 
4.4.1 First study: Co-perfusion of valacyclovir and nifedipine for 10 minutes 
 
 
 The permeability of valacyclovir in the control group was 0.83x10 -4 cm/sec,  
 
while the permeability of valacyclovir after a 10-minute co-perfusion with 100 μM  
 
nifedipine was 0.61x10-4 cm/sec (Figure 4.1).  The permeability of valacyclovir in  
 
the presence of nifedipine was reduced by 26.5%, but this difference was not  
 
statistically significant. 
 
 
 
4.4.2 Second study: Co-perfusion of valacyclovir and nifedipine for 30 minutes  
 
 
 
 The permeability of valacyclovir in the control group was 0.75x10 -4 cm/sec,  
 
while the permeability of valacyclovir after a 30-minute co-perfusion with 90 μM  
 
nifedipine was 0.54x10-4 cm/sec (Figure 4.2).  The permeability of valacyclovir in  
 
the presence of nifedipine was reduced by 28.0%, but this difference was not  
 
statistically significant.  These results were not markedly different from the first   
 
perfusion schedule (Table 4.1). 
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4.5 Discussion 
 
 
 
 There are several drug interaction studies found in the literature that have  
 
effectively demonstrated the absorption-enhancing effects of nifedipine on various  
 
PepT1 substrates (Westphal et. al, 1990; Duverne et. al, 1992; Harcouet et. al, 1997;  
 
Berlioz et. al, 199; Berlioz et. al, 2000; Wenzel et. al, 2002).However, these studies  
 
have only focused on a single class of drugs: the β-lactam antibiotics. Therefore, the  
 
current studies have sought to understand if the prodrug valacyclovir can be affected in  
 
a similar fashion while in the presence of this calcium channel blocker.  After a series of  
 
intestinal perfusion studies in wildtype mice it became evident that nifedipine modestly  
 
reduced the permeability of valacyclovir (i.e. 26-28%) in a non-significant manner.   
 
These results were surprising as they directly clashed with the conclusions drawn from 
 
other oral administration and intestinal perfusion studies, but also ran counter to the  
 
mechanism proposed by Wenzel et. al (2002).  Therefore, upon further reflection,  
 
additional studies were not performed. 
 
A possible explanation for the non-significant interaction between valacyclovir  
 
and nifedipine may be due to the prevailing ionization state of valacyclovir in the  
 
perfusate buffer.  Valacyclovir is known to have three pKa values: 1.90, 7.47, and 9.43.    
 
The neutral form of the compound, which has the greatest affinity and functional activity  
 
toward PepT1-mediated transport, is the predominant form between pH 7.47 to 9.43.  
 
However, the pH 6.5 perfusate buffer utilized in these studies, coupled with the  
 
nifedipine-induced acidification of the intestinal lumen (Wenzel et.al, 2002), would leave  
 
much of the prodrug in the less active, cationic form. The presence of this cationic form  
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results in an approximate 40% reduction in uptake when the pH is reduced from 7.4 to  
 
6.5 (Balimane and Sinko, 2000).  On the other hand, β-lactam antibiotics are commonly  
 
present in the zwitterionic form at physiological pH.  For example, amoxicillin is primarily  
 
zwitterionic between pH 2.4 and 7.4 (Elmolla and Chaudhuri, 2010), while cephalexin is  
 
primarily zwitterionic between pH 2.56 and 6.88 (Legnoverde et. al, 2014).  Moreover,  
 
the zwitterionic form of cefixime dramatically increases under pH 6.0 (Wenzel et.  
 
al,1996), which explains why the Caco-2 and rat perfusion studies were conducted in  
 
buffers with pH ranging from 5.0 to 5.5 (Wenzel et. al, 2002; Harcouet et. al, 1996).     
 
Since these zwitterionic forms would be expected to enhance PepT1 functional activity  
 
(Brandsch et. al, 2004), this may help explain why these β-lactam antibiotics (and not  
 
valacyclovir) are affected by nifedipine. 
 
In light of these drug interaction studies, however, it would certainly be rational to  
 
question the efficacy of nifedipine in these intestinal perfusions.  Indeed, efficacy was a  
 
legitimate concern after observing a non-significant decrease in permeability following a  
 
10-minute co-perfusion with nifedipine.  This was the very reason the co-perfusion  
 
period was increased to 30 minutes.  Nevertheless, efficacy is not likely an issue in  
 
these studies.  In previous intestinal perfusion experiments nifedipine was perfused at  
 
100 μM (a comparable concentration) for 15 minutes, followed by the 60-minute  
 
perfusion of cefixime or cephalexin (Harcouet et. al, 1997; Berlioz et. al, 1999).  Despite  
 
this time differential, nifedipine still had a notable effect on the antibiotics even an hour  
 
after nifedipine ceased to be perfused through the intestinal segment. 
 
 Since nifedipine is intrinsically linked to the activity of the Ca v1.3 channel  
 
(Striessnig et. al, 2015; Snider et. al, 2008), it would also be prudent to address a  
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study that has questioned the role of this channel as a mediator for calcium absorption  
 
in mice (Reyes-Fernandez and Fleet, 2015).  In summary, these researchers found that  
 
serum calcium levels were not significantly different between mice that were co- 
 
administered calcium with either 25 mM fructose or 25 mM glucose. Based on these  
 
results they asserted that Cav1.3 does not have an essential role in intestinal calcium  
 
transport since the more depolarizing conditions induced by glucose did not impact total  
 
calcium influx.  This assertion is primarily based on the notion that Cav1.3 channels are  
 
fully activated (i.e., the most influential) in the presence of at least 20 mM glucose, as  
 
indicated in a previous intestinal study conducted in rats (Mace et. al, 2007).  However,  
 
the conclusions Reyes-Fernandez and Fleet have drawn from their study are not  
 
convincing.  If these researchers wanted to study the impact of Cav1.3, they should  
 
have used a calcium channel blocker to monitor the contribution of this channel under  
 
different conditions.  As indicated in the review by Kellett (2011), the TRPV6 channel  
 
operates under more hyperpolarizing conditions, and thus can compensate for the lack  
 
of Cav1.3 activity under glucose-deficient conditions.  
 
 Although depolarizing nutrients like glucose can increase the activity of the  
 
Cav1.3 channel, it is interesting to observe substantial interactions between nifedipine  
 
and various PepT1 substrates under relatively hyperpolarized conditions. Namely, the  
 
clinical and rat oral administration studies, and the rat intestinal perfusion studies were  
 
performed under the fasted state with little depolarizing nutrient aside from the PepT1  
 
substrates themselves (Westphal et. al, 1990; Duverne et. al, 1992; Harcouet et. al,  
 
1997; Berlioz et. al, 1999; Berlioz et. al, 2000).  The Caco-2 cell studies in fact utilized  
 
the highest concentration of depolarizing agent: 10 mM glucose (Wenzel et. al, 2002).  
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This concentration was adopted for the current studies, and was believed to be  
 
sufficient to facilitate an interaction under fasted conditions in mice. 
 
 In conclusion, the co-perfusion of valacyclovir and nifedipine in wildtype mice 
 
resulted in a non-significant decrease in the permeability of this prodrug.  It has been  
 
suggested that these results may deviate from past studies involving β-lactam  
 
antibiotics because of this prodrug’s unfavorable ionization state at physiological pH.   
 
Therefore, conducting interaction studies between β-lactam antibiotics and nifedipine in  
 
mice would be a logical next step to determine if positive interactions are due to 
 
differences in compound ionization or to unattributed species differences. 
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4.6. Figures and Tables 
 
 
 
 
Figure 4.1 Wildtype mice were perfused with 50 µM valacyclovir alone (control) or co-
perfused with 100 µM nifedipine for the first 10 minutes (n=4) of the intestinal perfusion.  
There were no significant differences as determined by unpaired t test. 
 
 
 
 
C
o
n
tr
o
l 
+
 n
if
e
d
ip
in
e
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
P
e
r
m
e
a
b
li
ty
 (
x
1
0
-4
c
m
/s
e
c
)
99 
 
 
Figure 4.2 Wildtype mice were perfused with 50 µM valacyclovir alone (control) or co-
perfused with 90 µM nifedipine for the first 30 minutes (n=5) of the intestinal perfusion.  
There were no significant differences as determined by unpaired t test. 
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Table 4.1 Comparison of the results from the two different perfusion schedules involving 
valacyclovir and nifedipine 
 
 
Study Group Permeability (cm/sec 
x10-4) 
Percent Change 
1st Perfusion Study 
(10-minute co-
perfusion) 
Control 0.83 -26.5% 
+ Nifedipine 
 
 
 
0.61 
2nd Perfusion Study 
(30-minute co-
perfusion) 
Control 0.75 -28.0% 
+ Nifedipine 0.53 
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CHAPTER 5 
 
Future Directions 
 
 
 
The goal of the studies presented in Chapter 4 was to determine if the intestinal  
 
absorption of valacyclovir would be enhanced in the presence of nifedipine.  This was  
 
the prevailing hypothesis because previous administration studies involving β-lactam  
 
antibiotics and nifedipine asserted that there was an enhancement in the intestinal and  
 
oral absorption of these PepT1 substrates in both humans and rats.  However, this  
 
trend was not observed with the current studies conducted in mice.  Instead, the  
 
intestinal permeability of valacyclovir was modestly and insignificantly reduced by 26- 
 
28% in the presence of nifedipine. This seemingly contradictory result opens two new  
 
lines of inquiry that deserve further exploration. 
 
First, the efficacy of nifedipine on the intestinal inhibition of calcium and its  
 
reliance with nutrient uptake should be investigated in these wildtype mice.  It was  
 
demonstrated in rat jejunum that calcium uptake was blocked by 52% with 10 µM  
 
nifedipine, and that the addition of 20 mM glucose increased calcium inhibition to 78%.  
 
Currently, no such studies have been conducted in mice, but understanding the effect  
 
nifedipine has on calcium uptake is integral when interpreting interaction studies.  Upon  
 
satisfactorily completing this investigation, conducting interaction studies with higher  
 
glucose concentrations may prove to be an interesting prospect.  This is because the  
 
Cav1.3 channel is known to be more highly activated under increasingly depolarized  
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conditions.  
 
 Secondly, it is quite possible that the unexpected results obtained from these  
 
mice are due to the reduction in PepT1 functional activity as dictated by the unfavorable  
 
ionization state of valacyclovir at pH 6.5.  To determine if this is the case, other 
 
compounds should be tested in mice that are primarily zwitterionic under experimental  
 
conditions.  Good candidate compounds would be amoxicillin and cephalexin.  These β- 
 
lactam antibiotics have already been co-administered with nifedipine in humans and  
 
rats, so observing results that deviate from these previous studies may suggest an 
 
unknown species-dependent mechanism instead .   
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APPENDIX : UPLC Method Validation (Figures and Tables) 
 
 
 
 
 
 
 
 
Figure A.1 Chromatograms of A) inlet and B) outlet perfusate following the in situ 
intestinal perfusion of the prodrug valacyclovir. Acyclovir has a retention time of 2.3 
minutes and valacyclovir has a retention time of 4.2 minutes. 
A 
B 
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Figure A.2 An assessment of method specificity: chromatograms of blank perfusate.   
Each chromatogram is derived from separate mice. 
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Table A.1 The UPLC gradient method utilized for the separation of acyclovir and 
valacyclovir 
 
Time (min) Flow Rate (mL/min) Water 
+ 0.1% TFA 
 
Acetonitrile 
+0.1% TFA 
Initial 0.5 100% 0% 
5 0.5 90% 10% 
7 0.5 90% 10% 
7.1 0.5 100% 0% 
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Table A.2 The intraday and interday accuracy of acyclovir and valacyclovir as assessed 
by quality control samples 
 
 
 
Compound Quality Control 
Sample (µM) 
Intraday Accuracy 
(% of true value) 
Interday Accuracy 
(% of true value) 
 
 
 
 
 
 
Acyclovir 
 
 
 
50 
 
96.4 
- 
100.1 
 
 
 
98.7 
 
10 
99.9 
- 
102.8 
 
 
101.6 
 
2.5 
 
 
103.7 
- 
105.5 
 
 
104.5 
    
 
 
 
 
 
Valacyclovir 
 
200 
101.4 
- 
103.1 
 
 
102.1 
 
50 
101.6 
- 
101.8 
 
 
101.7 
 
10 
100.0 
- 
102.3 
 
 
101.3 
 
 
 
Intraday and interday accuracy were assessed over three consecutive days.  Intraday 
values were recorded as a range. 
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Table A.3 The intraday and interday precision of acyclovir and valacyclovir as assessed 
by quality control samples 
 
 
 
Compound Quality Control 
Sample (µM) 
Intraday Precision 
RSD (%) 
Interday Precision 
RSD (%) 
 
 
 
 
 
 
Acyclovir 
 
 
50 
 
0.03 
- 
0.25 
 
 
 
2.03 
 
10 
0.14 
- 
0.26 
 
 
1.67 
 
2.5 
0.12 
- 
0.45 
 
 
0.55 
    
 
 
 
 
 
Valacyclovir 
 
200 
0.22 
- 
0.71 
 
 
1.17 
 
50 
0.25 
- 
0.34 
 
 
0.99 
 
10 
0.31 
- 
0.34 
 
 
1.59 
 
 
 
Intraday and interday precision were assessed over three consecutive days.  Intraday 
values were recorded as a range. 
 
 
 
